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ABSTRACT
The aim of this thesis is to develop combination therapy using a small molecule
and RNA including siRNA, shRNA, or miRNA inhibitor for the treatment of type 1
diabetes and prostate cancer. New amphiphilic biodegradable polymers capable of codelivering small hydrophobic molecules and RNAs or human bone marrow-derived
mesenchymal stem cell (hBMSC) for co-delivery of an shRNA and a miRNA inhibitor
were used as drug delivery platform. The drug delivery properties were evaluated in
vitro and in vivo islet transplantation, subcutaneous and orthotopic prostate cancer
models.
In Chapter 1, an overview of prostate cancer, the role of miRNA and the way for
regulating miRNA as well as the design of delivery systems is given. I also introduce a
brief background of type 1 diabetes and the treatment methods. Chapter 2 discussed
the treatment of early stage or advanced prostate cancer using a luteinizing hormone
release hormone (LHRH) conjugated micelles for target delivery of CBDIV17 (a
bicalutamide analog) or combination therapy using CBDIV17 and embelin (a XIAP
inhibitor). In Chapter 2, subcutaneous model was used to prove our concept. Our
results indicated that LHRH conjugated micelles carrying CBDIV17 or both CBDIV17
and embelin inhibited tumor cell growth in vitro and in vivo.
Chapter 3 reports the newly screened small molecule named rubone as a miR34a modulator for combination therapy with paclitaxel to treat chemoresistant prostate
cancer. This compound was first characterized for miR-34a modulation efficacy in
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paclitaxel resistant prostate cancer cell lines including DU145-TXR and PC3-TXR. The
miR-34a downstream protein level and combination therapy efficacy were also
evaluated. The biodegradable copolymer poly (ethylene glycol)-block-poly (2-methyl2-carboxyl-propylene carbonate-graft-dodecanol) (PEG-PCD) were used to co-deliver
both drugs in an orthotopic prostate tumor model after characterizing the drug delivery
properties. This combination therapy using rubone as a miR-34a modulator reversed
the chemoresistance of prostate cancer and significantly inhibited paclitaxel-resistant
tumor growth in vivo. Finally, we summarized the results for prostate cancer treatment
and gives suggestions for further research.
Chapter 4 provided the background information about islet transplantation for
treating type 1 diabetes. In Chapter 4, we constructed plasmid encoding shRNA
against Fas receptor and miRNA inhibitor for downregulating miR-375. This plasmid
was transfected to hBMSCs as an RNA delivery vehicle and hBMSC transferred these
two small RNAs to human islet by direct touch and exosome. This stem cell-based
gene therapy and cell therapy suppressed islet apoptosis and promoted islet function
in vitro and in a humanized NOD scid gamma (NSG) mouse model. The immune
reaction after islet transplantation was suppressed by intravenous injection of hBMSC
and peripheral blood mononuclear cells (PBMC) co-cultured exosomes. We obtained
a 100% insulin independence after humanization by intraperitoneal injection of PBMC.
Chapter 5 summarizes the results of this thesis and gives suggestions to further
research.
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CHAPTER 1. THERAPEUTIC OF PROSTATE CANCER USING SMALL
MOLECULES
1.1.

INTRODUCTION

Prostate Cancer is the most frequently diagnosed neoplasm of prostate and the
second leading cause of cancer mortality affecting men in the United States.(1) Nearly
all prostate carcinomas are initially androgen dependent and further developed into
androgen independent.(2) Hence, the disease is classified as hormone-dependent or
hormone-refractory depending on the sensitivity of androgen ablation. Androgen
ablation or blockade of androgen receptor (AR) is the cornerstone of treating early
stage prostate cancer. Among various antiandrogens are used for chemotherapy,
bicalutamide has long half-life and tolerable side effects, leading to its wide clinical
application for treating early stage prostate cancer(3).
Although most patients respond well to androgen ablation therapy, chemotherapy,
and radiotherapy at the beginning, many patients relapse over time and become
resistant to chemotherapy(4). For example, prolonged treatment with bicalutamide
leads to AR proliferation and mutation, which converts bicalutamide from an AR
antagonist into an AR agonist. This is mainly caused by the over-expression of multiple
drug-resistant (MDR) transporters in prostate cancer cells. These transporters,
including P-glycoprotein (P-gp), breast cancer resistance protein, and multiple drug
resistance protein, increase drug efflux and reduce drug accumulation in tumor cells(5,
6). The prognosis of patients with MDR cancer is poor, due to the lack of effective
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clinical interventions. Also, many commonly used chemotherapy drugs such as
paclitaxel have inherent toxicity associated with their use(7).
MicroRNAs (miRNAs) are single stranded small non-coding RNAs (21–23
nucleotides) that have been reported as regulators of gene expression by hindering
translation and triggering degradation of target mRNA post-transcriptionally. miRNAs
play a crucial role in the initiation and development of a variety of human cancers with
numerous studies reporting aberrant miRNA expression. miRNAs are not only
deregulated in cancers, but are also acting as oncogenes or tumor suppressors.
Oncogenic miRNAs (oncomiRs) function by either inhibiting tumor suppressor genes
or genes responsible for promoting apoptosis or stimulating cell proliferation and are
normally upregulated in cancer (Table 1-1). In contrast, tumor suppressor miRNAs are
downregulated in cancers. These miRNAs function by inhibiting genes that hinder
apoptosis or cell proliferation.(8) For example, miR-221 has an oncogenic function by
suppressing Bmf, a proapoptotic BH3-only protein, to inhibit cell apoptosis(9). In
addition, miR-221 enhances cell migration by targeting PTEN and TIMP3(10). In
contrast, Let-7g suppresses tumor cell proliferation by targeting both c-Myc(11) and
COL1A2(12). Meanwhile, Bcl-xL, an anti-apoptotic member of the Bcl-2 family, is
identified as a target of let-7g to induce cell apoptosis(13). Normally, oncogenic
miRNAs are overexpressed while tumor suppressor miRNAs are downregulated in
cancer. Therefore, two miRNA-based therapeutic strategies used are: (1) miRNA
inhibition for addressing oncogenic miRNAs and (2) miRNA replenishment for
overexpressing tumor suppressor miRNAs. Similar therapeutic molecules including
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oligonucleotides and small molecules may be employed in both approaches to either
directly inhibit miRNAs or indirectly by targeting specific genes or transcription factors
which modulate specific miRNA expression.
Table 1-1. OncomiRs as targets for cancer therapy
OncomiRs
Target genes
miR-21
PDCD4, PTEN, BCL2, TPM1, RECK,
miR-17-92
PTEN, Bim
miR-221/222
p27, TIMP2, DKK2
miR-155
DMTF1, annexin 7, LKB1, E2F2, GABA receptor
miR-223
PAX6, Stathmin1, FBXW7/hCdc4
miR-214
PTEN, p53
miR-191
C/EBPβ, checkpoint kinase 2
miR-25
CDKN1C, LATS2, RECK

1.2.

References
(14-18)
(19, 20)
(21-23)
(24-28)
(29-31)
(32, 33)
(34, 35)
(36-38)

CURRENT TREATMENT OF PROSTATE CANCER

1.2.1. Small molecule drug
Treatment of prostate cancer might involve surgery, external beam therapy, and
small molecule drug. With the advances in drug design and chemical synthesis, small
molecule drugs become crucial part in clinical trial. They can be further modified for
better therapeutic outcome and oral absorption.
Androgen receptor is a ligand-inducible transcription factor and member of the
steroid hormone, which enhances prostate cancer growth and progression at the early
stage. For hormone related prostate cancer therapy, abiraterone is a Food and Drug
Administratoin (FDA) approved drug by inhibiting CYP17 activity and further suppress
androgen synthesis(39). Bicalutamide is another small molecule drug in early stage
prostate cancer therapy by inhibiting the binding of androgen receptor (AR)(40). With
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potent mutation of AR after prolonged bicalutamide treatment, some bicalutamide
analogs including CBDIV17 was developed to overcome the resistance from AR
mutation(41).
Almost all androgen dependent prostate cancer will be developed into androgen
independent, which is defined as lower levels of testosterone found in tissue and
blockage of androgen does not affect the growth of tumor tissue(42). In this advanced
stage of prostate cancer, paclitaxel or docetaxel has been extensively used. Their anticancer mechanisms for prostate cancer are associated with tubulin and to promote
microtubule assembly, which causes mitotic-dependent cell cycle arrest(43).
Furthermore, they also induce cell death through activation of caspase and lysosomal
pathways(44).
The highly metastatic potential of prostate cancer in advanced stage is another
crucial issue to overcome, especially bone metastasis. For clinical efficacy, therapies
must target tumor-microenvironment interactions, where several tyrosine kinases,
including PDGFR, EGFR, VEGFR, IGF-1R and c-Met, have been implicated to
promote metastasis and tumor growth, especially in patients with advanced castrateresistant prostate cancer (CRPC)(45). There were many small molecules screened as
tyrosine kinase (TK) inhibitor to inhibit different TK activities, including imatinib for
PDGFR(46) and sunitinib for VEGFR(47). However, only few of them showed
promising results in phase III clinical trials. Cabozatinib is an ATP competitive inhibitor
with selectivity to c-Met and VEGFR-2 showing high clinical potential(48). Phase II
clinical trial exhibited that 86% of patients with documented bone metastasis
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experience complete or partial response on bone scans 6 weeks after initiation(45).
Although the clinical tests are not completed yet, researches about c-Met inhibitors are
now being rapidly accelerated and clinically useful agent might be identified for
prostate cancer treatment.
1.2.2. Immunotherapy
Immunotherapy for the treatment of cancer has made significant progress over the
past 20 years. It implies the host response beginning with an antigen presenting cell
able to recognize foreign biological threat and processing this into presentable
antigens which are delivered to T cells(49). Thus, the basic mechanism of any
immunotherapy in cancer is to activate a specific immune response creating tumor cell
destruction. Cancer immunotherapy can be broadly classified as vaccines(50),
checkpoint

inhibitors(51),

or

adoptive

cellular

therapy(52).

Vaccine-based

immunotherapy relies on the innate ability of antigen-presenting cells (APCs), which
capture and present prostate tumor associated antigens (TAAs) leading to the
generation of humoral and cytotoxic T-cell response(53). Checkpoint inhibition aims to
reverse the inhibition caused by signals intended to prevent autoimmunity or tumor
microenvironment. Adoptive cellular therapy uses engineered synthetic single-chain
variable fragment (scFv) that recognize the TAA in a human leukocyte antigenindependent fashion to facilitate T cell mediated cytotoxicity.
Sipuleucel-T (Provenge) is the only FDA approved therapeutic cancer vaccine. It
is an autologous dendritic cell (DC)-based vaccine with a prostatic acid phosphatase-
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granulocyte-macrophage colony-stimulating factor fusion protein. A phase III trial
published by Kantoff et al. showed significantly improved overall survival in a
multicenter, double-blind, placebo controlled clinical study(54). Patient treated with
Provenge had an increased mean overall survival by 4.1 months compared with
placebo-treated group (25.8 vs 21.7 months).
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) normally acts to suppress T-cell activity
and therefore the inhibition of CTLA-4 could induce a net activation to strengthen the
immune activity for tumor killing. Ipilimumab was a small molecule that was identified
that could improve the survival of metastatic melanoma(55). Recently, a phase III trial
of double-blind study was performed to determine the effect of ipilimumab on CRPC
with at least one bone metastasis and improved overall survival was obtained (11.2m
vs. 10m) compared to the placebo group(56). Like CTLA-4, PD-1 might be another
therapeutic target for prostate cancer as PD-L1 is overexpressed by tumor cells(57).
This PD-L1 could bind PD-1 and inhibit the activation of T cells and further enhance
tumor survival.
1.2.3. miRNA
Drug target selection remains a bottleneck in the quest for anticancer therapeutics.
The current paradigm where drugs are designed to target cancer-related proteins is
flawed for several reasons. Since cancer is a complex process involving multiple
factors and multistep processes, the efficacy of anticancer agents designed to target
single therapeutic protein is often sub-optimal and less effective in cancer therapy.
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Although combination therapy, in which more than one targets are addressed, yields
better therapeutic outcomes compared to single drug treatment, it is typically costly
and complexed, associated with detrimental drug–drug interactions and involves
complicated treatment regimens. Considering their abnormal expression in cancer
compared to normal tissues, miRNAs are regarded as high value drug targets (Table
1-1) for cancer therapy and targeting their expression can change cancer phenotype.
One rationale for miRNA-based therapeutics described by Garzon et al., is the
notion of cancer networks being miRNA wired(58). The “miRNA wired cancer network”
hypothesis indicates miRNAs to be the code that maintains a required connection
between all genes and protein networks in normal cells. Thus, normal tissues can be
thoroughly characterized and miRNA expression patterns can be established as a
coding blueprint. It might then be possible to compare this blueprint to miRNA
expression patterns in tumor tissue. Therapeutic approaches can be developed to
“reboot” the cancerous tissue by restoring the abnormal expressed miRNA patterns to
the default settings observed in the normal tissue. Clearly, such a therapeutic strategy
involves targeting more than single miRNA, gene or protein. It may involve
simultaneous inhibition or replacement of more than one miRNAs. From an
implementation standpoint, it might be tempting to dispose the “miRNA wired cancer
network” hypothesis because of its potential complexity. Another argument might be
that there is no universal miRNA blueprint for normal tissues. Nonetheless, since
abnormal expression of single miRNA may affect hundreds of proteins(59),
reprogramming cancer network may be more feasible using miRNAs compared to

20

proteins. This is also the advantage of miRNA based therapy compared to siRNA
therapy since normally siRNA could only target one cancer related gene expression.
Traditional methods to restore the miRNA expression include （Figure 1-1）: (1)
miRNA mimics or antisense oligonucleotide (ASOs, also known as antagomirs or
antimiRs), which includes cholesterol-conjugated antimiRs, locked nucleic acid (LNA)
antimiRs and tiny LNA antimiRs; (2) miRNA sponges which contain multiple tandem
binding sites to target miRNA; (3) CRISPR/Cas9 based genome editing which modify
the genome of cancer cells. Indeed, these three non-small molecule miRNA therapies
have the potential to be an efficient method for miRNA inhibition. However, there are
still several crucial obstacles need to be overcome. Most of antisense oligonucleotides
are perfect complementary to their targets with chemical modifications to improve
binding affinity and stability. However, these miRNA inhibitors may not distinguish
between miRNAs within the same family, which causes off-target effects(60). Although
the off-target effect of miRNA sponges is not reported yet, miRNA sponges always
exhibit different degrees of inhibition in different conditions and it is still challenging to
evaluate the degree of miRNA silencing under a sponge treatment(61). Similarly, the
off-target effect of CRISPR/Cas9 has not been well-recognized and accurately profiled
when applied in gene therapy, which significantly limits its clinical application.
Another concern which hinders the clinical development of non-small molecular
miRNA inhibitors is the delivery-related issue due to the high instability of
oligonucleotide in blood serum. Depending on the diseases and targets, people need
to carefully design the delivery systems to achieve optimized clinical effects. Organs,
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which are more accessible and responsible for metabolism and excretion including
liver, kidney, and spleen, have shown exciting results for antisense oligonucleotide
delivery with high accumulation of oligonucleotide. Nevertheless, it is still difficult to
ensure an effective dose reaching and entering the tumor cells. Theoretically, liposome
or nanoparticle based non-viral delivery system can be used to deliver miRNA sponges
or CRISPR/Cas9 based genome editing systems. However, these systems generally
suffer from low gene delivery efficiency, especially for in vivo studies.
1.3.

Small molecule miRNA therapeutic agents

Due to the above challenges of non-small molecule miRNA inhibitors, it would be
promising to develop small molecule drugs to target specific miRNAs and restore their
expression (Figure 1-1). Actually, miRNAs have long been neglected as potent drug
targets due to their structural flexibility and highly electronegative surface(62).
Furthermore, poor understanding of miRNA X-Ray crystallography or NMR structure
as well as the limited availability of miRNA-Dicer or RISC complex structure makes the
design of small molecule inhibitor or inducer of miRNA much more difficult(63). These
might be the reasons why the first reported small molecule miRNA inhibitor (SMIR) by
Gumireddy et al.(64) and most following designs were based on non-specific selection
assay. For the first SMIR, they selected miR-21 as the target oncogenic miRNA, which
is overexpressed in various cancers including breast, ovarian, and lung cancers(65,
66). Lentiviral vector encoding complementary sequences of miR-21 and downstream
luciferase reporter gene was constructed for HeLa cell transduction and promising
miR-21 inhibitor selection. As a result, diazobenzene was identified for further
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modification since 251% increase of luciferase signal was detected relative to
untreated cells. Except for this non-specific selection assay, there are also some other
screening methods to identify potent small molecule miRNA regulators.

Figure 1-1. Schematic representation of miRNA biogenesis and the inhibition
effect of antisense oligonucleotide, miRNA sponges, CRISPR/Cas9 genome
editing, and small molecule inhibitor of miRNA (SMIR).
1.3.1. Luciferase (or GFP)-based screening
Luciferase-based vectors, which include a complementary sequence or control
sequence of target miRNA linked with downstream luciferase reporter gene, are widely
used for SMIR screening. After cloning into lentiviral vectors, they are transduced into
culture cells where target miRNA is highly expressed. These genome modified cells
are thereby able to determine the efficacy of potent SMIRs. With the presence of
effective SMIRs, less target miRNA is available for binding the complementary
sequence and luciferase gene is overexpressed as a result. Thus, the more effective
SMIR, the more luciferase signals will be detected. Bose et al.(67) used pEZX-MT01
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plasmid, which co-express luciferase and PDCD4, a known target of miR-21, to screen
SMIRs for miR-21 in the MCF-7 cell line. Streptomycin was identified as the most
potent molecule and was characterized as a direct miR-21 inhibitor docking with premiR-21 at a region close to the terminal loop. Similarly, this luciferase reporter-based
screening method can be used to select specific compounds promoting tumor
suppressor miRNA secretion or activity. Xiao et al.(68) constructed miR-34a reporter
vector using the Huh7 cell line and found that rubone, which inhibited luciferase activity,
was a potent miR-34a promoter. Compared to SMIR selected by the luciferase reporter
system, a small molecule modulator (SMMR) of miRNA needs further evaluation to
exclude the false-positive phenomenon caused by toxicity since this compound might
decrease luciferase activity.
1.3.2. Molecular beacon-based screening
Fluorescent beacons are usually hairpin shaped oligonucleotides which contain a
5′-fluorophore and a 3′-quencher, along with a miRNA targeting sequence (anti-miRNA
sequence) in the loop for SMIR selection. Davies et al.(69) first described the design
of a fluorescent beacon and forecasted the potent application for screening SMIRs. In
a hairpin shape, the base pair of the beacon would bring the fluorophore and quencher
closely, leading to quenching of the fluorescence. Thus, a Dicer-dependent increase
in the signal would be detected since mature miRNA is generated from Dicer-mediated
hydrolysis, resulting in a dissociation of the fluorophore and quencher, and an increase
of fluorescence. In the presence of a Dicer inhibitor of pre-miRNA, Dicer activity would
be inhibited and the beam showed a lack of fluorescence increase. Vo et al.(70) used
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this fluorescent beacon system to screen Dicer inhibitor to inhibit biogenesis of
oncogenic miR-372 and miR-373. In their study, neomycin appeared to be the best
compound for Dicer inhibition and can thereby be used for further modification.
1.3.3. Structure-based design
One difficulty encountered in the drug development process is the high expense in
the process of drug screening. With a more accurate understanding of miRNA (or
miRNA protein complex) structure and the simulation of binding affinity of small
molecule to miRNA, in silico high-throughput screening is a promising technique to
speed up the discovery of SMIRs and decrease the cost during the process. Shi et
al.(71) reported AC1MMYR2 as an inhibitor of Dicer-mediated biogenesis of miR-21
using MC-Fold/MC-Sym pipeline for RNA secondary and tertiary structure prediction.
In their studies, AC1MMYR2 was proved to be a specific miR-21 inhibitor, which
repressed pri-miR-21 expression by approximately 50% after 6 h and inhibited tumor
growth in an orthotopic tumor model. However, this computational approach is still
challenging and needs further evaluation and recalibration to ensure the efficacy of
screened compounds due to the flexible and complicated RNA tertiary structure.
1.3.4. Peptide or peptoid screening
Another category of SMIRs is peptides or peptoids, which are well evaluated for
selective RNA binding. Here, we introduce two peptide selection methods, peptoid
microarrays and phage display selection. Chirayil et al.(72) performed peptoid
microarrays to screen specific ligands for RNA hairpin precursor of miR-21. In their
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studies, they used peptoid microarrays as the foundation for RNA ligand discovery to
screen a library of 7680 N-substituted oligoglycines. Among them, two compounds
were proved to have specific binding affinity to the secondary structure of miR-21
precursor hairpin. A fusion phage is a filamentous virion displaying on its surface a
foreign peptide fused to a coat protein(73). In one study, the library of this fusion phage
may represent up to billions of peptides(74). If a phage displays a peptide which is a
strong ligand of target miRNA, it can be eluted and the peptide sequences responsible
for the binding are easily obtained by infecting the specific phage into bacteria and
sequencing the relevant part of their viral DNAs(75). Using this method, Bose et al.(76)
reported that ‘ALWPPNLHAWVP’ was a potent peptide sequence for binding miR-21.

Figure 1-2. Mechanisms of luciferase/GFP based screening
(A) luciferase/GFP based screening. (B) Molecular beacon-based screening. (C)
structure-based design. (D) Peptides or peptoids screening.
1.4.

Small molecule restored miRNAs for prostate cancer therapy

miRNAs are considered crucial factors in spectrums of cancers including prostate
cancer. In the past decade, various miRNAs have been reported to be associated with
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the cancer development process. Drug discovery and development are usually a timeconsuming and expensive process, which significantly influences the therapeutic
progress of cancer and other diseases, leading to the urgent need for new therapeutic
alternatives. SMIRs and SMMRs show another promising approach for the treatment
of cancer due to its less time-consuming characteristic for drug development with
reduced cost in the whole process. In addition, their exciting results further proved
them to be an efficient tool for therapeutic use. Here, we listed several miRNAs that
might be therapeutic targets for prostate cancer and introduce some small molecules
that might restore the miRNA expression.
1.4.1 miR-21
The oncogenic miR-21, has been identified to be significantly elevated in numerous
tumor cells, including prostate, pancreas and liver cancer(77). Abundant expression of
miR-21 promotes cell invasion and metastasis in cancer cells in vitro and in vivo, which
represses the expression of PDCD4 protein and reactivate the PTEN/PI3K/Akt
signaling pathways(78). Zhou et al. demonstrated that 8-methoxy-urolithin A (mUA)
can induce cell apoptosis by down-regulating miR-21 expression and inhibiting
PI3K/Akt/β-catenin pathway in DU145 cell line in a PTEN dependent manner(78). For
miR-21 inhibition in other cancers, diazobenzene was identified as miR-21 inhibitor by
killing Hela cells(64). Streptomycin was screened by Bose et al. as the most potent
compound as a direct miR-21 inhibitor(67). Recently, GFP-based screening, which was
similar to luciferase based screening, was also developed for SMIR screening. To
screen a general miRNA inhibitor, cell line stably expressing lenti-GFP and lenti-shGFP
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was developed and a compound was considered potent SMIR if green fluorescence
was increased. To screen a SMIR for specific miRNA, EGFP reporter gene expression
was under the control of target miRNA through its complementary sequence present
at the 3′ UTR. Using this GFP based screening assay, Shum et al.(79) obtained 6
potent miR-21 inhibitors and 6-hydroxy-dl-DOPA was characterized as the most potent
SMIR. AC1MMYR2 was identified by Shi et al. as an inhibitor of Dicer-mediated
biogenesis of miR-21 using structure design from MC-Fold/MC-Sym pipeline for RNA
secondary and tertiary structure prediction(71).
1.4.2. miR-96 & miR-182
miR-96 has been well established to contribute to prostate cancer survival,
proliferation, and clonogenicity by reducing FOXO1 expression(80). Furthermore,
MTSS1 is another tumor suppressor target of miR-96 for tumor growth, development,
and metastasis(81). miR-182 is another oncogenic miRNA which is associated with
growth, migration and invasion in prostate cancer via targeting FOXO1(82). To screen
small molecule targeting miR-96 and miR-182, Velagapudi et al. reported a new
method called informa for sequence based design of SMIR to target pre-miRNAs.
Inforna integrated a selection-based strategy (Two-Dimensional Combinatorial
Screening; 2DCS)(83), a statistical approach (Structure–Activity Relationship through
Sequencing; StARTS)(84), and the structural information about the RNA of interest
that identified RNA motifs that positively and negatively contributed to binding. After
screening and optimization, they selected two compounds for the miR-96 precursor
and miR-182 precursor, respectively. The secondary structure was demonstrated by
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enzymatic mapping assays and the downstream effect of miR-96 inhibitor was
evaluated. Compared to traditional medicinal chemical approaches, Inforna provided
a reliable prediction of SMIRs that could target specific miRNA.
1.4.3. miR-372
miR-372 is overexpressed in prostate cancer cell lines and its overexpression
promotes cell proliferation and migration. Mechanism study elucidated that large tumor
suppressor kinase 2 (LATS2) was a direct target of miR-372 using luciferase reporter
assays. Decreased expression of LATS2 promoted prostate cancer cell activity just as
over-expression of miR-372(85). Cao et al. identified arsenic sulfide as a miR-372
inhibitor to repress the overexpression of miR-372 and they confirmed that arsenic
sulfide could suppress tumor growth in a mouse xenograft model(85). Vo et al.
screened neomycin as the best aminoglycoside using molecular beacon-based
screening for Dicer inhibition to inhibit biogenesis of oncogenic miR-372(70).
1.4.4. miR-34a
Most prostate cancers relapse within two years into hormone refractory due to the
presence of tumor initiating cells, known as cancer stem cells (CSCs), which are
involved in tumor progression and metastasis, but are resistant to chemotherapy.
Recently, miR-34a was reported to be significantly underexpressed in chemoresistant
prostate cancer cell line(86) or CD44+ cancer stem cells(87). As a tumor suppressor
miRNA, miR-34a is responsible for promoting cancer cell apoptosis, inhibiting cell
metastasis(88) and chemoresistance(89). Thus, miR-34a replenishment might be a
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novel therapeutic method to reverse PTX-resistance for treating chemoresistant
prostate cancer. Among the small molecule drugs, natural and synthetic analogs of
chalcones exhibits promising anticancer activity. However, only a few studies have
focused on the role of chalcone derivatives on the expression of miRNAs. Xiao et al.
first reported rubone, a chalcone analog, as a miR-34a modulator to inhibit
hepatocellular carcinoma (HCC) growth(68). In their study, rubone upregulated miR34a expression, downregulated the downstream target genes expression, and
suppressed HCC growth in vivo in p53 dependent manner. Xia et al. identified that
genistein could lead to upregulation of miR-34a in pancreatic cancer and further inhibit
cell growth and apoptosis. Agostini et al. reported that retinoic acid could enhance miR34a expression in neuroblastoma cells through Tap73 pathway(90)
1.5.

Delivery of small molecule anti-cancer drugs.

Despite their therapeutic potential, clinical applications of small molecule anticancer drugs are limited due to their high organ toxicity, poor water solubility, and low
bioavailability. To overcome these obstacles, some drug delivery systems have been
developed to solubilize these compounds and further deliver them to prostate tumor
tissue. These delivery systems could be divided into non-target delivery system and
target delivery system.
1.5.1 Non-target delivery system
Polymeric nanomedicines could offer several advantages with the capable of
increasing the aqueous solubility of lipophilic drugs. First, they are normally less toxic
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compared to traditional solubilizing agents such as DMSO and Cremophor EL. Thus,
these nanomedicines could reduce the adverse effects on healthy tissues. Second,
these nanomedicines could actively target the tumor site and deliver adequate
quantities of drug to enhance the therapeutic efficacy by enhanced permeability and
retention (EPR) effect. This negative targeting is caused by the small size of the
nanomedicine which ensures preferential accumulation in tumor cells.
Nanomedicines might be lipid-based (liposomes) or polymer-based (micelles,
nanoparticles) and the method of drug encapsulation could be chemical conjugation
or physical encapsulation. Chemical conjugated nanomedicines are drug deliver
platforms composed of a drug chemically linked to a polymeric carrier by a
biodegradable covalent bond. This covalent bond is always physiological sensitive to
release the drug in cells or tumor tissue. With the chemical linkage, drug release profile
always exhibits prolonged release curve(91) and consequently longer circulation and
reduced toxicity(92) of the drug are achieved. Furthermore, chemical conjugation
might help the drug to circumvent some of the drug resistance pathway of cancer
cells(93). To achieve these benefits, this polymer needs to be carefully designed. For
example, the polymer needs to be non-toxic and easy to conjugate for decent drug
loading capacity. Furthermore, the drug-conjugate platform should be stable in normal
organ or blood serum but able to release the drug in tumor site or tumor cells.
Compared to chemical conjugation, physical encapsulation is more widely applied
for drug loading since some therapeutic agents do not have functional groups for
chemical conjugation and cannot be modified without affecting the therapeutic effect.
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Polymeric micelles are self-assembled polymers with spherical structure. They have a
hydrophobic core for solubilizing a considerable amount of water insoluble drugs. The
hydrophilic component of micelles forms the corona which provides steric stabilization.
This shell could also provide stealth properties which prevent the recognition and
degradation by reticuloendothelial system and therefore prolong the half-life of micelles
in vivo(94). This property of micelles facilitates their wide application in physical
encapsulation for drug loading.
1.5.2 Target delivery system
Passive targeting delivery mainly utilize the EPR effect to obtain higher
accumulation of drug in tumor site. However, this EPR effect is only efficient for
targeting solid tumor and less efficient for spreading or metastatic tumors(40). In some
cases where drug loading capacity of the nanomedicine is low, passive targeting is
also less effective and may lead to adverse effect on visceral organs before therapeutic
levels of drug could reach the tumors. Thus, addition of targeting ligands on the surface
of the nanomedicine is crucial to reduce the toxicity to healthy organs and enhance the
drug accumulation in tumors.
For prostate cancer, one of the approved clinical trials for target delivery is SGN15(95) , which is monoclonal antibody-drug conjugates. This SGN-15 delivers
doxorubicin to tumor tissues with overexpressed Lewis-y antigen (CD174). For
research, several antigens, receptors, and proteins that are overexpressed on the
surface of prostate cancer cells could be explored for promising targeting delivery of
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drugs.
Prostate specific membrane antigen (PSMA) is a type II integral membrane
glycoprotein(96) which is highly overexpressed in prostate tumors, especially in
metastatic and castration resistant prostate cancer(97). Wolf et al. described the
design of using a single chain fragment of antibody binding to PSMA for the delivery of
an immunotoxin for killing prostate cancer cells(98). The transferrin receptor (TfR) is
another membrane associated glycoprotein which is overexpressed 2 to 10-fold in
prostate cancer cells compared to normal prostate cells. This might be another
targeting method for drug delivery to prostate cancer. Six-transmembrane epithelial
antigen of the prostate (STEAP) is a transmembrane protein overexpressed in
advanced prostate cancer. Recently, a STEAP binding monoclonal antibody was
developed for target delivery and significant tumor growth suppression was
observed(99). Human epidermal growth factor receptor 2 (Her-2) is a transmembrane
tyrosine kinase receptor and a member of EGFR family which help to induce cell
growth, survival, adhesion, and migration(100). Recent report shows that Her-2 is
closely linked to the activation of AR pathway and the progression of CRPC(101).
Goldstein et al. reported an anti-Her2 immunoemulsion as a targeted drug delivery
system for the treatment of prostate cancer and observed significant tumor growth
inhibition in immunodeficient mice(102). LHRH is a 10 amino acid peptide hormone
secreted by hypothalamus and regulates gametogenesis(103). Overexpressed LHRH
receptors are detected in prostate (86%), ovarian (80%), and breast (50%) cancers
and have low expression in healthy organs(104). Karampelas et al. reported the design
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of LHRH-gemcitabine conjugates for treating androgen-independent prostate
cancer(105). Their formulation showed a significant advantage in tumor growth
inhibition compared to free gemcitabine.
1.6.

Introduction and treatment of type 1 diabetes
Islet graft rejection after islet transplantation is caused by acute immune response,

inﬂammatory reactions, inadequate oxygenation and several other factors collectively
contributing to primary non-function.(106) Among the cell apoptotic pathways,
Fas/FasL pathway plays an essential role in T1D and is also involved in insulin
release.(107) Meanwhile, the inhibition of islet specific miR375 improved insulin
release of islet cell line.(108) As a potent approach for inhibiting aberrant protein
expression, RNAi is becoming a promising tool to silence genes which are involved in
immune reaction and PNF process of transplanted islets. Nevertheless, therapeutic
efficacy of gene delivery is hindered by low transfection efficiency in case of non-viral
vectors(109) and activation of innate immune response by viral vectors(110).
Mesenchymal stem cells support islet viability and function by preventing immune cell
infiltration and promoting islet growth.(111) Their potential could be further enhanced
by genetically modifying them to express therapeutic proteins while maintaining their
stemness and pluripotency. These immunomodulatory properties of MSCs could be
mainly attributed to secretion of some anti-inflammatory cytokines which play a central
role in induction of regulatory T-cells when co-cultured with lymphocytes.(112)
Exosomes are nanovesicles which serve as shuttle for certain proteins, mRNA
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and miRNA into the target cells.(113) MSCs have been used to improve islet
transplantation due to their self-renewal potential, promoting islets revascularization,
and immuomodulatory effects. For MSC-derived exosomes, Xin et al. reported that
systemic administration of MSC-derived exosomes promoted functional recovery after
stroke in rats.(114) Lai et al. reported that MSC-derived exosomes reduces myocardial
ischemia/reperfusion injury.(115) These studies proved the potential of exosome as
immunomodulatory regimens which also induce the regeneration of injured organs.
Previous research also indicated that exosomes derived from genetically modified
dendritic cells or mesenchymal stem cells (MSCs) can deliver siRNA or miRNA to the
mouse brain(116) or cancer cells to inhibit glioma growth(117).
1.7.

CONCLUSIONS

miRNA-based cancer therapy is gaining more and more attention since it could
simultaneously control more than one targets in combination therapy. Recently,
oncogenic and tumor suppressor miRNAs are being identified in rapid progress.
Notably, oncogenic miRNA for one cancer might be tumor suppressor miRNA for
another cancer. For example, suppress the expression of miR-27a could inhibit MCF7 cell growth(118), while the miR-27a is tumor suppressor miRNA in prostate cancer
by targeting MAP2K4(119). For the treatment of prostate cancer, androgen ablation is
the first choice for early stage prostate cancer. However, advanced prostate cancer
might develop chemoresistance due to abnormal miRNA expression. Thus, to restore
the miRNA expression and miRNA network might be a novel choice for cancer
treatment.
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Due to the short half-life of oligonucleotide, miRNA delivery platforms are always
required for oligonucleotide based therapy. However, obstacles including high
efficiency, low toxicity, and high bioavailability still need to be overcome. Recently,
small molecules that specifically regulates miRNA expression might generate hope for
better future of miRNA-based cancer therapy since small molecules are always easy
to formulate with high bioavailability. Furthermore, several lipid or and polymer based
drug delivery platforms could efficiently deliver these compounds to the tumor site by
physical encapsulation or chemical conjugation, especially when conjugated with
tumor specific target delivery ligand. For prostate cancer therapy, several potent
compounds have been screened and evaluated to regulate prostate cancer related
miRNAs, including miR-21, miR-96, and miR-34a. Although further evaluation is still
needed for these compounds, we can expect bright perspective of miRNA based
therapy for prostate cancer.
As a novel gene delivery vehicle and immunomodulatory regimen, exosome
derived from mesenchymal stem cell could potentially promote islet transplantation by
delivering anti-apoptotic siRNA and enhance the regeneration of transplanted islets.
However, more persuasive researches are needed to prove the efficacy of this
biocompatible vesicle.
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CHAPTER 2. LHRH-CONJUGATED MICELLES FOR TARGETED DELIVERY OF
ANTIANDROGEN AND XIAP INHIBITOR TO TREAT ADVANCED PROSTATE
CANCER.
2.1. INTRODUCTION
Androgen ablation or blockade of androgen receptor (AR) is the cornerstone of
treating early stage prostate cancer. Among various antiandrogens for chemotherapy
have been developed, bicalutamide has longer half-life and tolerable side effects,
leading to its wide clinical application for treating early stage prostate cancer(3).
However, prolonged treatment with bicalutamide leads to AR proliferation and mutation,
which converts bicalutamide from an AR antagonist into an AR agonist. To overcome
this issue, we previously synthesized bicalutamide analog CBDIV17, which was more
potent than bicalutamide in inhibiting the proliferation of prostate cancer cells and
suppressing tumor growth in vivo(41).
The downregulation of apoptotic and overexpression of antiapoptotic protein is
common feature associated with the progression of prostate cancer. The inhibitor of
apoptosis (IAP) family suppressing caspase activity is probably key factor of the
imbalance between proliferation and apoptosis. X-chromosome-linked inhibitor of
apoptosis (XIAP), which binds caspase 9 and further inhibits the activity of caspase-3
and caspase-7, is the most potent IAP protein.(120) Embelin is a well-accepted small
molecule inhibitor of XIAP. It binds to BIR3 domain and prevents XIAP binding and
inhibiting the activity of Caspase family.(121, 122) Thus, we hypothesize that
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combination therapy using CBDIV17 and embelin has significant potential for treating
advanced prostate cancer. However, poor aqueous solubility of CBDIV17 and embelin
results in low absorption and less efficacy. Traditional approaches to increase solubility
using solubilizing agents including dimethyl sulfoxide (DMSO) and Cremophor EL have
associated toxicity limiting their clinical application.(123)
Polymeric micelles are nanosized particles and have spherical structures with a
hydrophobic core, which can improve the solubility and stability of hydrophobic
anticancer drugs. To enhance the solubility of CBDIV17, we synthesized polyethylene
glycol-b-poly (carbonate-co-lactide) (PEG-b-p(CB-co-LA)) copolymer(124, 125) to
prepare micelles, which successfully encapsulated bicalutamide, embelin, and some
other drugs. In our previous results(41), CBDIV17 and embelin loaded micelles
showed high antitumor efficacy and successfully suppressed tumor growth in vivo.
However, intratumoral injection of these micelles limited its clinical application to
prostate cancer.
Traditional chemotherapy usually employs high dose of anti-cancer drugs, which
usually cause severe toxicity to healthy organs. Passive targeting tumors in vivo mainly
utilized enhanced permeability and retention (EPR) effect(126, 127) causing
preferential accumulation of macromolecules at the tumor site. However, EPR effect is
only efficient for targeting solid tumors and is not used for spreading tumors and
metastases. Active targeting can be used to make micelles site-specific by coupling a
target moiety for receptors overexpressed on cancer cells. Furthermore, targeting
cancer cells can diminish the cytotoxicity towards other tissues and the drugs loaded
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micelles selectively accumulate to tumor site(128, 129). For targeted delivery of anticancer drugs, several receptors, which are overexpressed by cancer cells, are
selected as targets for polymer binding, such as prostate specific membrane antigen
(PSMA)(129), epidermal growth factor receptor (EGFR)(130), and luteinizinghormone-releasing hormone (LHRH) receptor(131). In recent years, LHRH and its
analogs have been employed in the clinical trial in the management of prostate cancer.
We expect active targeting by LHRH to be safe and efficient after systemic
administration. Due to the short half-life of natural LHRH, synthetic LHRH analogue
with improved bioactivity has been widely used for targeting LHRH-R(132, 133).
Therefore, we conjugated LHRH analog to our previously synthesized HOOC-PEG-bp(CB-co-LA) copolymer and hypothesize that LHRH conjugated micelles would
improve the efficacy of antitumor drug in vitro and in vivo and provide targeted drug
delivery to suppress tumor growth. In this study, HOOC-PEG-b-p(CB-co-LA) and
LHRH-PEG-b-p(CB-co-LA) were synthesized, characterized, and used for preparing
micelles for targeted delivery of CBDIV17 and embelin. We evaluated the drug
therapeutic efficacy of LHRH-conjugated micelles carrying CBDIV17 in an ectopic
athymic mouse model of prostate cancer and will further use orthotopic model to
evaluate the anti-tumor effect of LHRH-PEG-b-p(CB-co-LA) loaded CBDIV17 and
embelin.
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2.2. MATERIALS AND METHODS
2.2.1. Materials
2, 2-Bis(hydroxymethyl) propionic acid and benzyl bromide were purchased from
Sigma Aldrich (St. Louis, MO). Hydroxyl poly(ethylene glycol) carboxyl (HOOC-PEGOH, Mn = 5000) was purchased from Jenkem Technology (Allen, TX). SYBR Green,
real-time RT-PCR master mix, and reverse transcription reagents were purchased from
Roche (Indianapolis, IN). LHRH analog peptide, PYR-His-Trp-Ser-Tyr-DLys-Leu-ArgPro-Gly-CONH2, was purchased from Hanhong Group (Shanghai, China). CBDIV17
was synthesized as reported earlier(41). All other chemicals were of analytical grade
and used as received.
2.2.2. Synthesis of LHRH-PEG-b-p(CB-co-LA)
5-Methyl-5-benzyloxycarbonyl-1, 3-dioxane-2-one (MBC) and HOOC-PEG-bp(CB-co-LA)

were

synthesized

as

described

earlier(134).

Briefly,

2,

2-

bis(hydroxymethyl)propionic acid (26.8 g, 0.2 mol) and potassium hydroxide (12.72 g,
0.2 mol) were dissolved in 150 mL of dimethylformamide (DMF) and allowed to heat
at 100°C for 1 h. Benzyl bromide (41.5 g, 0.243 mol) was then added dropwise and
continuously stirred at 100°C for 15 h. DMF was evaporated under vacuum and the
crude product was dissolved in ethyl acetate (150 mL), hexanes (150 mL), and water
(100 mL). The organic layer was separated, washed with water, and dried with Na2SO4.
The final solution was evaporated to obtain benzyl 2, 2-bis(methylol)propionate (23.8
g, 56.64%), which was subsequently recrystallized using toluene.

40

To synthesize 5-methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one (MBC) (base
monomer), benzyl 2, 2-bis (methylol)propionate (22.4 g, 0.1 mol) dissolved in pyridine
(50 mL) and CH2Cl2 (200 mL), and chilled to -78oC over dry ice. A solution of
triphosgene (50 mmol, 14.8g) dissolved in CH2Cl2 was added dropwise to the above
solution and allowed to stir for 1 h at -78 oC and for additional 2 h at room temperature.
The solution was quenched with saturated aqueous NH4Cl. Organic layer was washed
with 1 M HCl, saturated aqueous NaHCO3 and then dried with Na2SO4. The pure MBC
(19.7 g, 88.3%) was obtained by evaporating the organic solvent under vacuum and
recrystalized using ice-cold ethyl acetate.
To synthesize HOOC-PEG-b-p(CB-co-LA) with the molecular weight of 10000, 1,
8-diazabicyclo[5.4.0]undec-7-ene (DBU) (40 μL) as a catalyst was added to the
mixture of HOOC-PEG-OH (1 g), lactide (0.6 g) and base monomer (0.4 g) dissolved
in 10 mL of anhydrous CH2Cl2 and allowed to react for 3 h under stirring at room
temperature. At the end of the reaction, benzoic acid (60 mg) was added and the
solvent was removed under vacuum. Crude polymer was purified by dissolving in
chloroform, and precipitate in large amount of isopropanol and diethyl ether, followed
by drying under vacuum for 48 h. Purified copolymer (100 mg, 0.01 mmol) and LHRHNH2 (27 mg, 0.02 mmol) were dissolved in a mixture of anhydrous DMSO (3 mL) and
anhydrous CH2Cl2 (12 mL). The mixture was allowed to stir for 30 min following which
1-Ethyl-3-(3- dimethylaminopropyl)carbodiimide ·HCl (EDC ·HCl) (3.0 mg, 0.0134 mM)
and 4-dimethylaminopyridine (1.0 mg, 0.008 mM) were added. After 48 h, CH2Cl2 was
removed under vacuum and the mixture was purified by dialysis molecular mass cutoff,
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3,500 Da) using water as a solvent. Purified LHRH conjugated polymer was dried by
lyophilization.
Polymers were characterized using 1HNMR recorded on a Varian (500 MHz,
T=25°C) using DMSO-d6 as a solvent. The chemical shifts were calibrated using
tetramethylsilane as an internal reference and reported as parts per million.
2.2.3. Critical Micelle Concentration
Fluorescence spectroscopy was used to estimate the critical micelle concentration
(CMC) of HOOC-PEG-b-p(CB-co-LA) and LHRH-PEG-b-p(CB-co-LA) copolymer
using pyrene as a hydrophobic fluorescent probe. Sixteen samples of HOOC-PEG-bp(CB-co-LA) or LHRH-PEG-b-p(CB-co-LA) dissolved in water with concentrations
ranging from 1.0X10-8 to 1 g/L were prepared and allowed to equilibrate with a constant
pyrene concentration of 6.0X10-7 M overnight at room temperature with shaking at 200
rpm. The fluorescent spectra of pyrene were recorded at an excitation wavelength of
335 nm and emission wavelength of 373 nm (I1) and 384 nm (I3) using
spectrofluorometer (Sunnyvale, CA). Peak height intensity ratio (I3/I1) was plotted
against the logarithm of polymer concentration. Value of the CMC was obtained as the
point of intersection of two tangents drawn to the curve at high and low concentrations,
respectively.
2.2.4. Formulation and Characterization of Drug-loaded Micelles
CBDIV17 loaded micelles were prepared using the film hydration method as
previously described with slight modifications(134). Briefly, 5 mg of CBDIV17 or
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embelin and 95 mg of HOOC-PEG-b-p(CB-co-LA) or LHRH-PEG-b-p(CB-co-LA) were
dissolved in 5 mL chloroform. Solvent was evaporated under vacuum and resulting film
was hydrated in 10 mL of phosphate buffered saline (PBS), and sonicated for 10 min
using a Misonix ultrasonic liquid processor (Farmingdale, NY) with an amplitude of 60.
Free drug was removed by centrifugation at 5,000 rpm for 5 min and filtration using a
0.22 μm nylon filter. Drug loaded micelles were concentrated by Amicon Ultra-15
Centrifugal Filter Unit (3,000 Da) and stored at 4°C. For further characterization, mean
particle size and size distribution of drug-loaded micelles were measured by dynamic
light scattering using a Malvern Zetasizer (Worcestershire, UK).
2.2.5. Drug Loading and Encapsulation Efficiency
To determine the drug loading and encapsulation efficiency, drug loaded micelles
were dissolved in acetonitrile (ACN). Concentration of CBDIV17 and embelin was
measured by reverse phase high performance liquid chromatography (RP-HPLC,
Waters, Milford, MA) with a UV detector at 290 nm for CBDVI17 and 288 nm for
embelin using a reverse phase C18 Column (250 mm×4.6 mm, Inertsil ODS). The
mobile phase was composed of 60:40 V/V of acetonitrile and water for CBDIV17 and
methanol: water: acetic acid: tetrahydrofuran=85:15:3:0.1 v/v/v/v for embelin.
2.2.6. In Vitro Drug Release Study
Drug release from HOOC-PEG-b-p(CB-co-LA) and LHRH-PEG-b-p(CB-co-LA)
micelles was determined after dialysis (3,500 Da cut off) against 25 mL PBS containing
0.1% Tween 80 (pH=7.2) in a thermo-controlled shaker with a speed of 100 rpm (5). 1
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mL samples were taken at specific time points (1, 3, 6, 12, 24, 48, 96, 144, 192 h) and
replaced with fresh PBS containing 0.1% tween 80. Drug concentration was measured
using RP-HPLC as described for drug loading. Cumulative amount of drug released
was evaluated as the percentage of total drug release to the initial amount. All
experiments were performed in triplicate and the data reported as the mean of three
individual experiments.
2.2.7. Cell Culture and Maintenance
Human prostate cancer cells C4-2 and lymph node prostate adenocarcinoma
(LNCaP) were purchased from American Type Culture Collection (ATCC, Manassas,
VA). LNCaP and C4-2 cells were cultured in RPMI 1640 media containing 10% fetal
bovine serum, 1% antibiotic-antimitotic, and 1% sodium pyruvate at 37°C in humidified
environment with 5% CO2. RWPE-1 cell line was kindly provided by Dr. Ming-Fong Lin
(University of Nebraska Medical Center, Omaha, NE).
2.2.8. Cellular Uptake of Targeted Micelles
Cellular uptake study was performed as described by Zou(135) and Kutty(136) with
minor modification. LNCaP and C4-2 cells were seeded at a density of 1×105 cells/well
in 96 well plates. After reaching confluence, medium was replaced by coumarin-6
loaded micelles suspensions with concentration of 0.3 mg/ml. After 2 h incubation, the
micelles solution was removed and cells were washed twice with 1 × PBS. The cells
were examined using inverted fluorescent microscope after DAPI staining. For
quantitative study, the cells were immersed in 0.5% Triton X-100 in 0.2 N NaOH
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solutions and concentration of coumarin-6 was measured at excitation wavelength of
430 nm, and emission wavelength of 485 nm. The reading of wells with the cells alone
represented the background intensity and was set up as a negative control. The
reading of the wells with coumarin-6 loaded micelles (0.3 mg/mL) was used as a
positive control.
2.2.9. Cell Viability Assay
Cells were seeded in 96-well plate at a density of 5,000 cells/well to determine
cytotoxicity of free, HOOC-PEG-b-p(CB-co-LA) or LHRH-PEG-b-p(CB-co-LA) micelles
loaded with CBDIV17 at the concentration of 10, 25, 50 μmol/L and embelin at the
concentration of 5 and 10 μmol/L for 48 h. The cellular toxicity of the two polymers was
also determined in these two cell lines. At the end of the treatment, the original medium
was replaced by fresh medium with 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) and incubated for another two hours. The
supernatant was removed carefully and MTT crystals were dissolved in 200 μl DMSO
and analyzed at a wavelength of 560 nm. To better mimic the in vivo tumor environment,
we used 3D on top assays to form sphere like structure, Briefly, 200 μL of 100%
Matrigel was used as the basement and 2x105 single cells were suspended in 300 μL
10% Matrigel in RPMI1640 as the growth medium in 24-well plate. After culturing for
48 h, growth medium was exchanged to growth medium containing CBDIV17 and
embelin at different concentrations, which was replaced with fresh media every two
days for 2 weeks before analyzing the therapeutic effect. Tumor growth was evaluated
by H&E staining and immunohistochemistry.
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2.2.10. Cell invasion and migration
The effect of CBDIV17 and embelin combination therapy on cell invasion and
migration was determined using Transwell membrane filter inserts (pore size 8 μM) in
6-well culture plates. For invasion assay, 200 μL Matrigel (BD Biosciences, CA) was
added to each transwell insert where RPMI1640 without FBS was used as the cell
culture medium, while RPMI1640 with 10% FBS was added in each well. LNCaP and
C4-2 cells were cultured for another 72 h after drug treatment. The number of cells
invaded Matrigel was quantified after staining with crystal violet. For migration assay,
1X106 cells were seeded into each transwell insert and cultured for another 72 h after
adding the drugs. The cell number was counted under a microscope in randomly
selected three fields after crystal violet staining for 10 minutes.
2.2.11. Real-Time RT-PCR
Expression of LHRH receptor was determined by quantitative real-time RT-PCR.
Briefly, LNCaP and C4-2 cells were seeded in 24-well plate at the density of 5×105
cells/well overnight. Total mRNA was isolated from cultured cells using RNeasy mini
isolation kit (Qiagen, Valencia, CA) and the concentration was determined by
Nanodrop 2000 (Thermo Scientific, Wilmington, DE). 170 ng of total mRNA was
converted to cDNA using TaqMan Reverse Transcription Reagents (Life Technologies,
Grand Island, NY). cDNA was used as a template and analyzed by SYBR Green
universal PCR master mix (Life Technologies, Grand Island, NY) on Roche Real-time
PCR instrument. S19 was used as an internal control. All samples were run in triplicate.
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The primer sequences were as follows: human LHRH receptor (Type 1) (forward): 5′GACCTTGTCTGGAAAGATCC-3′,
human

S19

(forward):

5′-

(reverse)

5′-CAGGCTGATCACCACCATCA-3′;

GGAGCTCTATCCTCTCTCTATT-3′,

(reverse):

5′-

CCCAGCATGGTTTGTTCTAATG-3′.
2.2.12. Western Blot Analysis and ELISA
C4-2 (2×106 /well) cells seeded in 6-well plate were treated with CBDIV17 loaded
LHRH-PEG-b-p(CB-co-LA) with the drug concentration of 25 μmol/L for 48 h.
Subsequently, cells were lysed with RIPA buffer (Sigma-Aldrich, St. Louis, MO) and
protein concentration was measured with micro BCA protein assay kit (Thermo
Scientific, Wilmington, DE). The lysate was then mixed with 6 × Laemmli Buffer
(Bioworld, Dublin, OH) and boiled for 5 min. The samples were loaded to 4–15% SDSPAGE for electrophoresis and subsequently transferred to immobilon polyvinylidene
fluoride (PVDF) membrane. Membranes were blocked with 5% bovine serum albumin
(BSA) in tris buffered saline at room temperature for 1 h and further incubated with
primary antibody at 4°C overnight, followed by incubation with secondary antibody
conjugated with infrared dyes (IRDye) at room temperature for 1 h. After washing with
tris buffered saline and tween 20 for 3 times, the signal of target protein was detected
using LiCOR Odyssey infrared imaging system (Li-COR, Lincoln, NE).
LNCaP and C4-2 cells were seeded in 12 well plate with the concentration of 1×106
cells/well and treated with free embelin, embelin loaded HOOC-PEG-b-p(CB-co-LA),
and embelin loaded LHRH-PEG-b-p(CB-co-LA) for 48 h. Cells were lysed and XIAP
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concentrations were detected using human total XIAP ELISA kit according to the
manufacturer’s protocol.
2.2.13. Caspase 3 Activity
Caspase 3 activity was analyzed with Caspase-Glo 3 assay kit as per
manufacturer’s protocol. To a single cell suspension generated by 0.25% TrypsinEDTA digestion, 100 μL of Caspase-Glo was added with the concentration of 104 cells/
well in 96 well plate and incubated at room temperature for 1 h. The solution was then
transferred to culture tubes to determine luminescence by a luminometer (Berthold,
Bad Wildbad, Germany).
2.2.14. In Vivo Efficacy of Drug Loaded LHRH Conjugated Micelles in Ectopic
Tumor Bearing Mice
All experiments were performed following the NIH animal use guidelines and the
protocol was approved by the Animal Care and Use Committee (ACUC) at the
University of Nebraska Medical Center. Ectopic flank tumors were induced in 6 weeks
old male athymic nude mice (Jackson Laboratory, Bar Harbor, ME) by subcutaneous
injection of 2 million C4-2 cells suspended in 1:1 serum free media and Matrigel. The
mice were randomized into the following three groups when the tumor size reached to
150 mm3: i) untreated control, ii) CBDIV17 loaded non-conjugated micelles, iii)
CBDIV17 loaded LHRH conjugated micelles. Formulations were injected intravenously
via tail vein at the concentration of 10 mg/kg at 3 day intervals for 25 days. Animal
body weight and tumor volume were monitored three times a week. Tumors were
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measured with a caliper prior to each injection. To determine apoptosis and
proliferation of tumor cells, tumors from mice were excised and fixed in 10% buffered
formalin, followed by routinely proceeding to paraffin. For embedding histology, 5 μm
thick sections were stained with Hematoxylin & Eosin for detection of tumor
architecture. Cell proliferation and apoptosis were determined using an antibody
against Ki-67 and caspase-3, respectively. The prostate cancer treatment was
evaluated by PSA level.
2.2.15. Statistical Analysis
Statistical significance of difference between two groups was determined by
student unpaired t-test.
2.3. RESULTS
2.3.1. Synthesis and Characterization of HOOC-PEG-b-p (CB-co-LA) and LHRHPEG-b-p(CB-co-LA)
HOOC-PEG-b-p(CB-co-LA) copolymer was synthesized by ring opening
polymerization of L-lactide and 5-methyl-5- benzyloxycarbonyl-1,3-dioxane-2-one
using HOOC-PEG as the macroinitiator and DBU as a catalyst (Figure 2-1A). The
peak (Figure 2-1B) at δ: 10.64 ppm demonstrated the carboxyl group and the multiplet
peak at δ: 4–4.5 ppm confirms the successful ring opening polymerization. The
following NMR peaks of copolymers were observed of the copolymers at δ: 1.25 (CH3
in CB unit, s, 3H); δ: 1.60 (CH3 in LA unit, s, 3H); δ: 3.51 (CH2 in PEG, m, 4H); δ: 4.15–
4.35 (CH2 in CB main chain, m, 4H); δ: 5.10–5.16 (CH in LA unit q, 1H and CH2 in CB
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side group, s, 2H); δ 7.36 (phenyl, m, 5H).
LHRH-PEG-b-p(CB-co-LA) was synthesized by conjugating NH2 group of DLys in
LHRH peptide to COOH group of HOOC-PEG-b-P(CB-co-LA). Conjugation was
confirmed by 1HNMR. The peak (Fig. 2-1C) at δ: 10.64 disappeared and new peaks
were observed at δ: 6.80, δ: 6.94, δ: 7.18, δ: 7.82, δ: 8.18, δ: 8.31, δ: 8.64, δ: 8.85,
and δ: 9.63, which demonstrated the successful conjugation of LHRH peptide.

Figure 2-1. Synthesis and characterization of LHRH-PEG-b-p(CB-co-LA)
copolymer.
(A) Illustration of polymer synthesis (B) NMR of HOOC-PEG-b-p(CB-co-LA) (C) NMR
of LHRH-PEG-b-p(CB-co-LA)
2.3.2. Preparation and Characterization of HOOC-PEG-b-p (CB-co-LA) and LHRHPEG-b-p(CB-co-LA) Copolymer Micelles
Table 2-1 Formulation of CBDIV17 and embelin in micelles
Drug loading
CBDIV17 formulation
Size (nm)
PDI
(%)
HOOC-PEG-b-p(CB-coLA)
82.33±3.93 0.237±0.022

4.59±0.01%

Encapsulation
Efficiency (%)
91.80%±0.20%
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LHRH-PEG-b-p(CB-coLA)
84.59±3.29 0.197±0.018

4.54±0.17%

90.80%±3.40%

Drug loading

Encapsulation
Efficiency

HOOC-PEG-b-p(CB-coLA)
94.45±4.39 0.231±0.012

2.90±0.41

58.00%±8.20%

LHRH-PEG-b-p(CB-coLA)
95.72±3.13 0.222±0.017

2.82±0.33

55.40%±6.60%

Embelin formulation

Size

PDI

We used film sonication method to formulate micelles of HOOC-PEG-b-p(CB-coLA) and LHRH-PEG-b-p(CB-co-LA) copolymers. Mean particle size of blank and drug
loaded micelles was in the range of 72.64-98.91 nm as determined by dynamic light
scattering (Table 2-1). Our result showed that the particle size was not influenced by
LHRH conjugation. Micelles were further characterized by critical micelle concentration
(CMC). Similar CMC values of HOOC-PEG-b-p (CB-co-LA) and LHRH-PEG-b-p(CBco-LA) suggest that the conjugation of LHRH does not influence the self-assembly of
the polymer (Fig. 2-2A).
2.3.3. In vitro Drug Loading and Drug Release from Micelles
The amount of CBDIV17 loaded into micelles was calculated using Eq. (1) based
on 5% theoretical drug loading. According to our result (Table 2-1), CBDIV17 and
embelin loading were not influenced by LHRH conjugation. CBDIV17 loading was
4.59±0.01%. There was 50% of CBDIV17 released from micelles after 24 h. LHRH
conjugation did not affect the release of CBDIV17 and embelin (Fig. 2-2B and C).
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Figure 2-2. Characterization of HOOC-PEG-b-p(CB-co-LA) and LHRH-PEG-bp(CB-co-LA).
(A) CMC value (B) Drug release of CBDIV17. (C) Drug release of embelin.
2.3.4. In Vitro Cellular Uptake
To demonstrate the effect of LHRH conjugation on cellular uptake, we first
determined LHRH receptor expression on LNCaP and C4-2 cancer cells and found to
be overexpressed by at least two folds as determined by real time RT-PCR, while
LHRH receptor was poorly expressed on RWPE-1 cells. We then determined the
cellular uptake of coumarin-6 loaded micelles. Figure 2-3A show fluorescent
microscope image of LNCaP and C4-2 cells after 2 h incubation with coumarin-6
loaded non-conjugated or LHRH conjugated micelles. The nucleus stained by DAPI
was circumvented by green fluorescence of coumarin-6, suggesting that the micelles
were internalized in the cytoplasm. Both cell lines incubated with coumarin-6 loaded
LHRH-PEG-b-p (CB-co-LA) micelles exhibited brighter fluorescence. Figure 2-3B and
C shows fluorescent intensity reading of the two micelles in LNCaP and C4-2 cell lines.
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The uptake efficiency of non-conjugated micelles was 22.7% for LNCaP and 28.3% for
C4-2. The uptake efficiency of LHRH-PEG-b-p(CB-co-LA) micelles was 33.1% for
LNCaP and 35.3% for C4-2. There was no significant difference in the fluorescent
intensity between HOOC-PEG-b-p(CB-co-LA) and LHRH-PEG-b-p(CB-co-LA) (data
not shown). The uptake of micelles in both cell lines, which has overexpressed LHRH
receptor, significantly increased with LHRH conjugation. However, LHRH conjugation
did not influence cellular uptake of micelles for RWPE-1 cells, which does not have
detectable LHRH receptor, according to both fluorescent image and reading (Data not
shown).

Figure 2-3. Effect of LHRH conjugated micelles on the cellular uptake of
antiandrogen CBDIV17.
(A) Imaging of coumarin-6 uptake in LNCaP and C4-2 cells (B) Fluorescent reading of
coumarin-6 uptake in LNCaP cells (C) Fluorescent reading of coumarin-6 uptake in
C4-2 cells
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2.3.5. Effect of CBDIV17 Loaded LHRH-PEG-b-p(CB-co-LA) and HOOC-PEG-bp(CB-co-LA) on LNCaP and C4-2 Growth

Figure 2-4. Effect of HOOC-PEG-b-p(CB-co-LA) and LHRH-PEG-b-p(CB-co-LA)
micellar formulation of CBDIV17 on inhibition of LNCaP and C4-2 cell
proliferation.
(A) Cytotoxicity of CBDIV17 formulation to LNCaP cells (B) Cytotoxicity of CBDIV17
formulation to C4-2 cells (C) Effect of CBDIV17 formulation to caspase 3 (D) Effect of
CBDIV17 formulation to PSA and AR expression
We determined the anticancer activity of CBDIV17 loaded micelles in LNCaP and
C4-2 cells. As shown in Figure 2-4A and B, CBDIV17 exhibited dose dependent anticancer activity in both the cell lines. Drug loaded micelles were more cytotoxic than
free drug. IC50 of free CBDIV17, CBDIV17 loaded HOOC-PEG-b-p(CB-co-LA), and
CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA) was 25.2, 21.9, and 12.8 μM respectively
in LNCaP cells. In C4-2 cells, it was 37.1, 30.9, and 19.8 μM respectively for free
CBDIV17, CBDIV17 loaded HOOC-PEG-b-p(CB-co-LA), and CBDIV17 loaded LHRHPEG-b-p(CB-co-LA) micelles. Additionally, there was a dramatic increase in the
inhibition of prostate cancer cell growth for drug loaded LHRH-PEG-b-p(CB-co-LA)
micelles compared to drug loaded HOOC-PEG-b-p(CB-co-LA) micelles, suggesting
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LHRH conjugated micelles increased cellular uptake of CBDIV17 compared to nonconjugated micelles. Similarly, we observed significant cytotoxicity of embelin
formulation on LNCaP and C4-2 cells (Figure 2-5A) as well as XIAP inhibition (Figure
2-5B). To mimic the therapeutic procedure of early stage prostate cancer, we
introduced androgen ablation in CBDIV17 and embelin combination therapy. Androgen
ablation inhibited LNCaP cell growth (Figure 2-6A) while promoted C4-2 cell growth
(Figure 2-6B) in vitro, and the effect could be reversed by DHT. In 3D cell culture model,
our results indicated that combination therapy using CBDIV17 and embelin
significantly inhibited LNCaP and C4-2 tumor growth determined by Ki67 staining and
tumor morphology (Figure 2-7). Furthermore, CBDIV17 and embelin combination
therapy suppressed tumor metastasis according to tumor invasion and migration assay
(Figure 2-8).

Figure 2-5. Cytotoxicity of embelin formulation (A) and its effect on XIAP
expression (B).

2.3.6. Caspase 3 and AR Activity
We next examined the influence of CBDIV loaded micelles on Caspase 3. Drug
loaded micelles, especially LHRH conjugated micelles, induced more cell apoptosis
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than

free

drug

according

to

Caspase

3

activity

(Figure

2-4C).

Figure 2-6. Effect of combination therapy on LNCaP (A) and C4-2 (B) cell viability
under androgen ablation.

Furthermore, we determined the effect of drug loaded micelles on the
transcriptional activity of AR by measuring protein expression of AR and prostate
specific antigen (PSA) after treating LNCaP and C4-2 cells with 25 μmol/L LHRH-PEGb-p(CB-co-LA) for 48 h. As shown in Fig. 2-4D, PSA protein expression was
significantly downregulated with CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA) micelles
treated, while there was little effect on AR expression.
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Figure 2-7. Effect of combination therapy on LNCaP tumor growth and
morphology by 3D model.
2.3.7. In Vivo Efficacy of CBDIV17 Loaded Micelles
Since LHRH-PEG-b-p(CB-co-LA) significantly enhanced the effect of CBDIV17 in
vitro, we further determined the effect of CBDIV17 loaded micelles in C4-2 ectopic
tumor bearing athymic mice. CBDIV17 were formulated to HOOC-PEG-b-p(CB-co-LA)
and LHRH-PEG-b-p(CB-co-LA) with the concentration of 2 mg/mL. The formulation
was injected intravenously 4 times at the dose of 10 mg/kg at 3 day intervals. Changes
in the relative tumor volume and body weight are shown in Figure 2-9. Tumor growth
was significantly inhibited by both CBDIV17 loaded HOOC-PEG-b-p(CB-co-LA) and
LHRH-PEG-b-p(CB-co-LA) micelles. CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA)
micelles were more effective in inhibiting tumor growth compared to CBDIV17 loaded
HOOC-PEG-b-p(CB-co-LA) micelles. No significant loss in body weight was observed
in the whole study, suggesting acceptable toxicity of the treatment (Figure 2-9B).
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Figure 2-8. Effect of combination therapy on LNCaP tumor growth and
morphology by 3D model
On day 17, the tumors from these three groups were excised and incubated with
Ki-67 and Caspase-3 antibodies to elucidate the mechanism of tumor suppression
(Figure 2-10). The number of cell proliferation marker Ki-67 positive cells in the control
group was significantly higher compared to the mice that received CBDIV17 loaded
HOOC-PEG-b-p(CB-co-LA) and LHRH-PEG-B-P(CB-co-LA) micelles, indicating that
micellar delivery of CBDIV17 efficiently suppressed tumor growth. There were only
minor Ki-67 positive cells in tumor tissues from the mice injected with CBDIV17 loaded
LHRH-PEG-b-p(CB-co-LA) micelles. CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA)
micelles were the most efficient in inducing cell apoptosis to the tumor tissues, leading
to high Caspase-3 expression. Furthermore, nucleus intensity of CBDIV17/LHRHPEG-b-p(CB-co-LA) group was obviously less other two groups, suggesting tumor
growth has been successfully suppressed. Enhanced Caspase-3 expression was also
observed in CBDIV17 loaded HOOC-PEG-b-p(CB-co-LA) treated tumor compared to
control group, which proved antitumor efficacy of non-target delivery of CBDIV17.

Figure 2-9. Effects of CBDIV17/HOOC-PEG-b-p(CB-co-LA) and CBDIV17/LHRHPEG-b-p(CB-co-LA) micelles on tumor growth in vivo.
(A) Tumor volume (B) Body weight
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2.4. DISCUSSION
Androgen inhibition is the first choice for treating early stage prostate cancer.
However, AR mutation and drug resistance after prolonged treatment makes this
approach less effective. Thus, more potent drugs to block androgen activity or
inhibiting multiple targets including IAP are necessary to treat advanced prostate
cancer. We have previously shown that CBDIV17 was more potent than bicalutamide
in inhibiting the proliferation of LNCaP and C4-2 cells(41). However, the poor solubility
of CBDIV17 and embelin (less than 50 mg/L) limit their potential applications. To solve
this issue, we thereby have formulated polymeric micelles, which solubilize the drugs
with their hydrophobic core. Furthermore, polymeric micelles exhibit passive targeting
due to the EPR effect causing preferential accumulation in tumors and inflammation
sites. For targeted delivery of drug loaded micelles to the tumors, LHRH peptide was
conjugated to HOOC-PEG-b-p(CB-co-LA) copolymer for targeting delivery of CBDIV17
to tumor site after systemic administration. LHRH peptide provides an effective
targeting ligand to LHRH receptors overexpressed in prostate cancer cells and limited
drug accumulation in normal organs, where LHRH receptors are not expressed
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detectably. Due to the wide application of LHRH analog, such as leuprolide, buserelin
and histrelin, in the clinical trials, active targeting by LHRH analog are expected to be
safe and efficient.
Figure 2-10. Effects of CBDIV17 loaded HOOC-PEG-b-p(CB-co-LA) and LHRHPEG-b-p(CB-co-LA) micelles on Ki-67, Caspase-3, and PSA expression in tumor.
A modified synthetic analog of LHRH, which has free amine group to be linked with
polymer without affecting its function, was used as a targeting moiety to LHRH
receptors. Therefore, the choice of conjugation with –COOH or –NHS was offered(137,
138). According to our NMR spectra and cytotoxicity results, the conjugation of LHRH

with HOOC-PEG-b-p(CB-co-LA) was successful and there was significant difference
in cytotoxicity when LHRH was conjugated to the micelles. Our results suggest that—
COOH is efficient to conjugate with LHRH for targeting LNCaP and C4-2 cells. LHRH
conjugation did not affect the release profile of CBDIV17 (Fig. 2-2B). After LHRH
conjugation, cellular uptake was significantly enhanced in LHRH receptor
overexpressed cell lines (Fig. 2-3).
LHRH has been an effective systemic treatment for prostate cancer for the past 7
decades(139). Thus, we first demonstrated the non-cytotoxicity of free LHRH analog,
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HOOC-PEG-b-p(CB-co-LA), and LHRH-PEG-b-p(CB-co-LA) (data not shown). We
observed significant cytotoxicity caused by LHRH conjugated micelles with 10 μM of
CBDIV17 in LNCaP cells and 25 μM in C4-2 cells after incubating for 48 h (Figure 24A and B). Significantly lower IC 50 demonstrated higher efficacy and cellular uptake
of CBDIV17 after coating with LHRH-PEG-b-p(CB-co-LA). Blockage of androgen
activity did not show high efficiency in C4-2 cells, which is androgen independent.
Significantly higher Caspase 3 activity was also observed upon treatment with
CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA) micelles as compared to free drug and
drug loaded by non-conjugated micelles, suggesting higher cell apoptosis.
PSA, which is a pivotal downstream target gene of androgen receptor(140), is
always elevated in the presence of prostate cancer and other prostate disorders.
Blocking AR would reduce the transcription activity of AR, which reduces the
expression of PSA. Our data (Figure 2-4D) showed that AR protein expression was
not influenced by CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA) micelles while PSA
expression was significantly inhibited. These results were similar to previously
published results of bicalutamide(141, 142). It means CBDIV17 does not downregulate
AR expression but binds to AR and prevent AR activation, which is same as the
mechanism of bicalutamide.
Following in vitro characterization, CBDIV17 were formulated and concentrated to
HOOC-PEG-b-p(CB-co-LA)

or

LHRH-PEG-b-p(CB-co-LA)

to

evaluate

tumor

suppression efficacy in mice bearing C4-2 xenografts. Consistent with in vitro data,
CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA) micelles was more potent in repressing

61

prostate tumor growth compared to CBDIV17 loaded HOOC-PEG-b-p(CB-co-LA) and
control groups. To further determine the mechanism of antitumor effect, we evaluated
the expression of cell proliferation marker Ki-67 and apoptosis marker Caspase-3 to
elucidate cell proliferation and apoptosis level in tumor tissue. Few Ki-67 positive cells
and high Caspase-3 expression level demonstrated significant in vivo antitumor
efficacy of CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA). We also observed similar but
less effect of CBDIV17 loaded HOOC-PEG-b-p(CB-co-LA) and tumor growth
suppression after CBDIV17 loaded HOOC-PEG-b-p(CB-co-LA) treatment, which is
probably caused by EPR effect.
2.5. CONCLUSION
In conclusion, we have successfully conjugated LHRH peptide to HOOC-PEG-bp(CB-co-LA) and demonstrated that LHRH conjugation did not affect CMC, CBDIV17
loading, and drug release profile. We also revealed the mechanism of CBDIV17 as an
androgen receptor antagonist. Finally, CBDIV17 loaded LHRH-PEG-b-p(CB-co-LA)
showed significant potential to suppress tumor cell growth in vitro and in vivo.
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CHAPTER 3. MICELLAR DELIVERED RUBONE AS MIR-34A MODULATOR FOR
TREATING PACLITAXEL RESISTANT PROSTATE CANCER
3.1. INTRODUCTION
Most prostate cancers relapse within two years into hormone refractory due to the
presence of tumor initiating cells, known as cancer stem cells (CSCs), which are
involved in tumor progression and metastasis, but are resistant to chemotherapy.
Recently, aberrant expression of miRNAs is critically implicated in cancer initiation,
progression, migration, and chemoresistance(143, 144). Among these miRNAs, miR34a is significantly underexpressed in chemoresistant prostate cancer cell line(86) or
CD44+ cancer stem cells(87). As a tumor suppressor miRNA, miR-34a is responsible
for

promoting

tumor

cell

apoptosis,

inhibiting

tumor

metastasis(88)

and

chemoresistance(89). Thus, miR-34a replenishment might be a novel therapeutic
method to reverse PTX-resistance for the treatment of chemoresistant prostate cancer.
Kojima et al. reported that miR-34a reverses PTX resistance by targeting the
downstream genes including SIRT1 and Bcl-2(145). Yao et al. reported that
combination therapy using doxorubicin and miR-34a synergistically enhanced the
antitumor property of doxorubicin and inhibited DU145 cell formed tumor growth in
vivo(146). Nonetheless, intrinsic challenges associated with oligonucleotide-based
miRNA replenishment including off-target effects, poor cellular uptake, and in vivo
instability hindered its clinical translation. Even though numerous miRNA delivery
systems were developed, most of them were proved less effective or toxic for clinical
use(8). Thus, to reverse the aberrant expression of miR-34a by small molecules might

63

be a potent alternative method for the treatment for PTX-resistant prostate cancer.
Natural and synthetic analogs of chalcones and isoflavones exhibit promising
anticancer activity. However, only a few studies have focused on the role of chalcone
derivatives on modulation of miRNAs. Rubone(68), isoliquiritigenin(147), and kuwanon
V(148) modulate miR-34a, miR-25, miR-9, miR-29a and miR-181a, respectively with
potent biological actions. Among these small molecules, Xiao et al. first reported
rubone, a chalcone analog, as a miR-34a modulator for the inhibition of hepatocellular
carcinoma (HCC) growth(68). In their study, rubone upregulated miR-34a expression
in a p53 dependent manner, downregulated the downstream target Bcl-2 and Cyclin
D1 expression, and suppressed HCC growth in vivo. However, the antitumor efficacy
of rubone as a miR-34a modulator for treating PTX resistant prostate cancer and the
underlining mechanisms remains largely unknown. Furthermore, poor aqueous
solubility of PTX and rubone (less than 50 mg/L) results in low and variable drug
absorption. Thus, novel drug delivery systems for co-delivery of both drugs are
required for combination therapy against PTX resistant prostate cancer.
Since the use of solubilizing agents and surfactants may cause organ and systemic
toxicity, biodegradable polymers, which can self-assemble into nano-sized micelles,
are gaining much attention. Polymeric micelles have spherical structures with a
hydrophilic corona and hydrophobic core, which improves the aqueous solubility and
stability of hydrophobic drugs(40). The stealth properties of poly (ethylene glycol) (PEG)
hydrophilic corona of micelles prevents their recognition by reticuloendothelial system
(RES) and therefore minimize their rapid elimination via the EPR effect. In our previous
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study, we designed and synthesized poly(ethylene glycol)-block-poly(2-methyl-2carboxyl-propylene

carbonate-graft-dodecanol)

(PEG-PCD),

which

significantly

enhanced the aqueous solubility of embelin, an X-linked inhibitor of apoptosis protein
(XIAP) inhibitor(149). Here, we determined the effect of rubone on miR-34a and its
target genes and investigated whether it can chemosensitize PTX resistant prostate
cancer cells and synergistically inhibit orthotopic prostate tumor in nude mice when
administrated intravenously as a micellar formulation with PTX.
3.2. MATERIALS AND METHODS
3.2.1. Cell lines and culture condition
Prostate cancer cell lines LNCaP, C4-2, DU145, and PC3 were purchased
from the ATCC and cultured in RPMI1640 containing 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin in a humidified 37oC incubator supplemented with 5%
CO2. The PTX resistant version of DU145 and PC3 (DU145-TXR and PC3-TXR) were
provided by Dr. Evan T. Keller from the University of Michigan. Normal prostate
epithelial RWPE-1 cells were provided by Dr. Ming-Fong Lin from UNMC and cultured
in complete keratinocyte growth medium, K-SFM (Life Technologies) supplemented
with 50 μg/mL of bovine pituitary extract and 5 ng/mL of EGF.
3.2.2. RT-PCR and Western blot analysis
Following the treatment of different concentrations of rubone or PTX and
rubone combination therapy, total mRNA was isolated using RNeasy isolation kits
(Qiagen, Valencia, CA) and 170 ng total RNA was converted to cDNA using miR-34a
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primer before analyzing for miR-34a concentration. To determine protein concentration,
cell protein was extracted using RIPA buffer after treatment with rubone at the dose of
5 μM and 10 μM for 48 h. The amount of protein was adjusted to the same
concentration, transferred to PVDF membrane, incubated with primary and secondary
antibodies, followed by Licor Odyssey system analysis (LI-COR Biotechnology, Lincoln,
NE). The primary antibodies used in Western blot and following immunohistochemistry
studies are as follows: anti-E-cadherin (Abcam, ab15148), anti-SIRT1 (Santa Cruz, sc15404), anti-Cyclin D1 (Abcam, ab16663), anti-p53 (Santa Cruz, sc-6243), anti-Bax
(Santa Cruz, sc-6236), anti-β-actin (Santa Cruz, sc-1616), anti-TAp73 (Santa Cruz, sc7957), anti-Elk-1 (Santa Cruz, sc-355).
3.2.3. Cell viability in 2D and 3D models
In 2D model, cell viability was determined by MTT assay after treating the cells
with different concentrations of rubone or 5 μM rubone plus different concentrations of
PTX. The anti-tumor effect of the combination therapy using PTX and rubone was also
determined using 3D tumor model(150) including 3D on top and hanging-drop models.
For 3D on top assays in 24 well plate, 200 μL of 100% Matrigel was used as the
basement and 2x105 single cells were suspended in 300 μL 10% Matrigel in RPMI1640
as the growth medium. After culturing for 48 h, growth medium was exchanged to
growth medium containing PTX and rubone at different concentrations, which was
replaced with fresh media every two days for 2 weeks before analyzing the therapeutic
effect. For the hanging drop model, 40 μL medium containing 4000 cells were added
in each well of 3D 96-well hanging drop plate (3D Biomatrix, Ann Arbor, MI) and drug
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containing medium was changed every two days for 3 weeks till sphere formation of
the control group.
3.2.4. Cell invasion and migration
The effect of PTX and rubone combination therapy on cell invasion and
migration was determined using Transwell membrane filter inserts (pore size 8 μM) in
6-well culture plates. For invasion assay, 200 μL Matrigel (BD Biosciences, CA) was
added to each transwell insert where RPMI1640 without FBS was used as the cell
culture medium, while RPMI1640 with 10% FBS was added in each well. PTX resistant
DU145-TXR and PC3-TXR cells were cultured for another 72 h after drug treatment.
The number of cells invaded Matrigel was quantified after staining with crystal violet.
For migration assay, 1X106 cells were seeded into each transwell insert and cultured
for another 72 h after adding the drugs. The cell number was counted under a
microscope in randomly selected three fields after crystal violet staining for 10 minutes.
3.2.5. Role of CSCs in chemoresistance
We further analyzed CSC population in DU145-TXR and PC3-TXR after
treatment with PTX, rubone and their combination using Aldeflour reagent (Stemcell
technologies, Vancouver, BC) based flow cytometry. Cells were suspended in
suspension media and stained by Aldeflour reagent, while a negative control
comprising cells treated with ALDH-inhibitor diethylamino-benzaldehyde (DEAB) was
included to gate the unspecific staining.
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3.2.6. Polymer synthesis, micelle formulation, and characterization
Poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonategraft-dodecanol) (PEG-PCD) was synthesized and characterized by 1H NMR as
described previously(149).

PTX and rubone loaded micelles were prepared by film

hydration with 10% theoretical drug loading. Chloroform as solvent was evaporated
under vacuum and resulting film was hydrated in 10 mL of phosphate buffered saline
(PBS), and sonicated for 10 min using Misonix ultrasonic liquid processor (Farmingdale,
NY) with an amplitude of 30, followed by removing the free drug at 5000 rpm
centrifugation for 5 min. Blank or drug loaded micelles were characterized by
measuring particle size using Malvern Zetasizer (Worcestershire, UK).
To determine the drug loading and encapsulation efficiency, drug loaded
micelles were dissolved in 1 mL mobile phase composed of 70:30 V/V of acetonitrile
and water. Concentrations of PTX and rubone were measured by reverse phase high
performance liquid chromatography (RP-HPLC, Waters Milford, MA) with a UV
detector at 228.6 nm for PTX and 324.3 nm for rubone using a reverse phase C18
column (250 mmX4.6 mm, Inertsil ODS). We also compared the drug loading capability
of PEG-PCD with commercially available poly (ethylene glycol)-polylactide (PEG-PLA)
and

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene

glycol)

(DSPE-PEG) of similar molecular weights. PTX and rubone release from PEG-PCD
micelles was determined after dialysis (2500-5000 Da cut of) against 50 mL PBS
containing 20% ethanol as a co-solvent, which did not dissolve PEG-PCD and break
the micellar structure at 37oC in a temperature controlled shaker at the speed of 100
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rpm. 1 mL sample was taken at specific time points (1, 2, 3, 6, 12, 24, 48, and 96 h)
and replaced with 1 mL PBS containing 20% ethanol. The sample was dissolved with
the mobile phase after removing the solvent using a rotary evaporator, followed by
determining drug concentration using HPLC.
We further estimated the in vivo stability of PEG-PCD micelles using timedependent Fluorescence Resonance Energy Transfer (FRET) in the presence of 20%
FBS. 50 μg of 3,3’-dioctadecyloxacarbocyanine perchlorate (DiO) as a lipophilic
fluorescent energy donor and 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine
perchlorate (DiI) as an acceptor, 1 mg of PTX and rubone were loaded into 10 mg of
PEG-PCD. Emission fluorescence spectra ranging from 490 to 590 nm was recorded
at an excitation wavelength of 488 nm (donor excitation) and resulted in a strong
emission at 565 nm (acceptor emission). We further compared the micelle stability of
PEG-PCD with PEG-PLA and DSPE-PEG after drug loading. Cytotoxicity of free drug
and drug formulated PEG-PCD micelles were also compared in DU145-TXR and PC3TXR cells.
3.2.7. In vivo tumor studies
All animal experiments were performed in accordance with the NIH animal use
guideline and protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Nebraska Medical Center. To visualize and monitor tumor
progression, we developed orthotopic prostate tumor using stably transfected prostate
cancer cells with lentivirus encoding GFP and luciferase (LP-hLUC-Lv201-0200,
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Genecopoeia, Rockville, MD). A midline incision was made in the lower abdomen of 8
weeks old male nude mice to expose the dorsal prostate lobe, where 30 μL PBS
containing 1X106 PC3-TXR expressing GFP and luciferase (PC3-TXR-GFP-Luc) was
injected. Three weeks after tumor cell injection, mice with orthotopic tumor was
randomly divided into four groups of 10 animals per group with blank micelles, PTX
(20 mg/kg) loaded micelles, rubone loaded micelles (20 mg/kg), and PTX and rubone
(10 mg/kg for each drug) loaded micelles. These formulations were injected
intravenously for five doses every other day. The body weight and tumor fluorescence
of the mice were recorded once a week. Followed by the last formulation injection, four
mice in each group were sacrificed and tumors were excised for determining miR-34a
expression by RT-PCR. The therapeutic effect of formulation was further determined
by immunohistochemistry (IHC) for Bax, Ki-67, and miR-34a downstream targets
including SIRT1, E-cadherin, and Cyclin-D1. The side effects of each formulation were
evaluated by hematoxylin and eosin (H&E) staining of the major organs including heart,
liver, spleen, lung, and kidney. Other mice were monitored for another two weeks to
further evaluate the anticancer efficacy of the formulation.
3.2.8. Statistical Analysis
Results were presented as the mean ± S.E.M. from three experiments for in
vitro studies and six experiments for in vivo studies. The statistical difference between
the two groups was calculated by unpaired Student’s t-test, and a P < 0.05 was
considered to be statistically significant.
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3.3. Results
3.3.1. Rubone upregulated miR-34a and reversed the expression of miR-34a
downstream targets in PTX-resistant prostate cancer cell lines
Our objective was to determine whether rubone could serve as a miR-34a
modulator to reverse the miR-34a downstream tumor-associated gene expression.
Thus, we first determined miR-34a expression in different prostate cancer cell lines.
miR-34a expression was markedly downregulated in androgen-refractory DU145, PC3,
and PTX resistant DU145-TXR and PC3-TXR cells compared to androgen dependent
LNCaP as well as normal prostate epithelial RWPE-1 cells (Figure 3-1A), indicating
the role of miR-34a in the initiation and progression of prostate cancer(151). Next, we
evaluated the cytotoxicity of rubone in these cell lines. As shown in Figure 3-1B,
rubone exhibited significantly higher cytotoxicity in DU145-TXR and PC3-TXR cells,
suggesting that rubone has stronger anticancer effect in advanced prostate cancer
cells, which have lower miR-34a expression (Figure 3-1A). However, rubone did not
show obvious toxicity to normal prostate cells (RWPE-1) and hormone sensitive
prostate cancer cells (LNCaP) with high miR-34a expression, indicating rubone
induced cytotoxicity through miR-34a related pathways. Rubone upregulated miR-34a
in PTX-resistant DU145-TXR and PC3-TXR cell lines in a dose dependent manner
(Figure 3-1C). After evaluating the anticancer effect of rubone, we determined miR34a downstream target gene expression after rubone treatment. PTX resistant cell
lines showed more chemoresistance related SIRT1 expression(152) and less
metastasis related E-cadherin expression(153) (Figure 3-1D and E). Rubone
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significantly reversed the expression of miR-34a downstream gene targets of DU145TXR and PC3-TXR cell lines (Figure 3-1D and E), including E-cadherin, SIRT1, and
Cyclin D1, whereas E-cadherin expression was not reversed in DU145-TXR cell line.
Furthermore, rubone monotherapy promoted cell apoptosis determined by Bax
expression in DU145-TXR and PC3-TXR cell lines. However, rubone showed less
effect of reversing miR-34a downstream targets and inducing apoptosis in nonresistant DU145 and PC3 cell lines. These data indicated the downregulation of miR34a in the progress of prostate cancer and suggest that rubone might work as a
specific miR-34a modulator to reverse miR-34a expression for the treatment of
androgen-refractory and highly metastatic prostate cancer.

Figure 3-1. Effect of rubone monotherapy on miR-34a expression.
A. miR-34a expression in prostate cancer and normal prostate cell lines. B.
Cytotoxicity of rubone on prostate cancer and normal prostate cell lines. C. Rubone
upregulated miR-34a expression in DU145-TXR and PC3-TXR in a dose dependent
manner. Rubone alone reversed the expression of miR-34a downstream proteins in
DU145 (D) and PC3 (E) cell lines.
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3.3.2. Rubone enhanced the anticancer effect of PTX in PTX-resistant prostate
cancer cell lines by reversing the expression of miR-34a downstream targets.
To determine that miR-34a is an anticancer target for reversing
chemoresistance of prostate cancer, we evaluated the gene regulation efficiency of
miR-34a mimic and miR-34a inhibitor and their effect on PC3-TXR viability. Using
lipofectamine 2000 as the transfection reagent, miR-34a mimic and inhibitor could
upregulate and suppress miR-34a expression in PC3-TXR cell line, respectively (Data
not shown). miR-34a inhibited PC3-TXR cell viability, whereas miR-34a inhibitor
promoted cell growth (Data not shown). We further demonstrated that miR-34a can
enhance PTX chemotherapy, whereas miR-34a inhibitor promoted cancer cell viability
(Figure 3-2A) with PTX treatment in PC3-TXR cell line. Rubone did not enhance the
anticancer effect of PTX in chemosensitive DU145 and PC3 cell lines (Figure 3-2B
and D), but significantly reversed chemoresistance of DU145-TXR and PC3-TXR cell
lines (Figure 3-2C and E). miR-34a inhibitor reversed the effect of rubone on
promoting PTX cytotoxicity (Figure 3-2F), indicating rubone promote the effect of PTX
through upregulating the expression of miR-34a. To mimic the complexity of in vivo
tumor environment, we determined the anticancer effect of PTX and rubone in 3D
tumor model. PTX and rubone combination therapy inhibited PC3-TXR cell growth and
sphere formation in 3D model, including 3D on top (Figure 3-2G) and hanging drop
model (Figure 3-2H). Similar with rubone monotherapy, PTX and rubone combination
therapy more effectively reversed the expression of miR-34a downstream gene
expression in DU145-TXR and PC3-TXR cell lines compared to non-resistant cell lines
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(Figure 3-2I and J). PTX reduced the expression of E-cadherin(154) in DU145 and
PC3 cell lines, whereas PTX and rubone failed to reverse E-cadherin in DU145-TXR
cell line (Figure 3-2I). Thus, rubone could work as a miR-34a modulator to reverse the
PTX-resistance in prostate cancer and restore the expression of miR-34a targeted
genes.

Figure 3-2. Effects of PTX and rubone combination therapy on PTX resistant cell
viability.
A. Cell viability of PC3-TXR cells after PTX, PTX+miR-34a, and PTX+miR-34a inhibitor
treatment. DU145 (B), DU145-TXR (C), PC3 (D), PC3-TXR (E) cell viability was
determined by MTT assay after PTX or PTX and rubone combination therapy. F. Cell
viability of PC3-TXR cells after PTX+rubone and PTX+rubone +miR-34a inhibitor
treatment.PC3-TXR cell viability and sphere formation after rubone or PTX and rubone
combination therapy was determined by 3D tumor model (G, 3D on top; H, hanging
drop). PTX and rubone combination therapy reversed the expression of miR-34a
downstream proteins in DU145 (I) and PC3 (J) cell lines.
3.3.3. Rubone inhibit cell invasion, migration, and CSC population in a p53independent pathway
Treatment of prostate cancer always failed due to the metastasis and the
presence of CSCs, which is highly chemoresistant(155). Thus, we further determined
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the effect of PTX and rubone combination therapy on the invasion and migration of
DU145-TXR and PC3-TXR cells. Rubone alone or its combination with PTX
significantly inhibited DU145-TXR and PC3-TXR invasion (Figure 3-3A and C) and
migration (Figure 3-3B and D). Furthermore, rubone or its combination with PTX
significantly downregulated aldehyde activity, which is a CSC marker (Figure 3-3E).
Collectively, our results demonstrated that combination therapy using PTX and rubone
significantly reversed chemoresistance, inhibited tumor cell migration and invasion,
and decreased the CSC population of androgen-refractory prostate cancer cells.
Previously research claimed that miR-34a and p53 axis regulates miR-34a
expression and tumor suppression(156, 157). However, our results indicated that there
was no change in p53 expression after rubone treatment, even in PC3-TXR cell line
(p53 null) (Figure 3-1E and 2J). These results suggest that rubone might upregulate
miR-34a in p53 independent pathways, including TAp73(90, 158) and Elk-1(159, 160).
Thus, we determined TAp73 and Elk-1 expression after rubone alone or with PTX.
Rubone monotherapy or PTX and rubone combination therapy significantly enhanced
TAp73 and Elk-1 expression (Figure 3-3F and G), suggesting p53 independent
pathway plays a crucial role in miR-34a upregulation by rubone.
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Figure 3-3. PTX and rubone combination therapy inhibit cell migration,
invasion, and CSC population in p53 independent manner.
The effect of rubone monotherapy or PTX and rubone combination therapy on tumor
cell invasion (A, upper line, DU145-TXR; bottom line, PC3-TXR) and migration (B,
upper line, DU145-TXR; bottom line, PC3-TXR) were determined by crystal violet
staining and quantified (C, invasion; D, migration). E. CSC population were analyzed
by Aldefluor staining and quantified by flow cytometry (upper line, DU145-TXR;
bottom line, PC3-TXR). PTX and rubone combination therapy reversed miR-34a
downstream protein expression of DU145 and PC3 cell lines in p53 independent
manner. Rubone alone (F) or with PTX (G) upregulated Tap73 and ELK-1
expression.
3.3.4. PEG-PCD micelles are effective drug delivery system for PTX and rubone
Polymeric micelles have been widely used for improving the solubility and
enhancing the in vivo stability of hydrophobic drugs. In this study, we used PEG-PCD
to form micelles for co-delivery of PTX and rubone. After chemical synthesis as
previously described(149), PEG-PCD polymer was characterized by 1H NMR and the
particle size distribution of micelles before and after drug loading was measured by
dynamic light scattering (Table 3-1). PEG-PCD could form micelles with low
polydispersity and drug loading did not affect the particle size. We further compared
drug loading and micelle stability of PEG-PCD micelles with two commercially available
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polymers PEG-PLA and DSPE-PEG. After setting up standard methods of HPLC for
measuring PTX and rubone concentrations, we determined the drug loading and
micelle stability of PEG-PCD, PEG-PLA, and DSPE-PEG. PEG-PCD had the highest
drug loading of 9.70 ± 0.10 and 5.34 ± 0.02% for both PTX and rubone (Figure 3-4A
and B), respectively compared to PEG-PLA which showed 4.18±0.03%, 1.51±0.02%,
and DSPE-PEG with 3.41±0.36% and 3.58±0.27%. We then determined PTX and
rubone release from PEG-PCD micelles. Interestingly, PEG-PCD micelles carrying
both PTX and rubone had a slower drug release profile compared to single drug loaded
micelles (Figure 3-4C and D), probably because hydrophobic and π-π interaction
between the two drugs slow down the drug release. We evaluated the cytotoxicity of
PTX and rubone formulation on DU145-TXR and PC3-TXR cells. PEG-PCD micelles
did not show cytotoxicity to each prostate cancer or normal prostate cell lines (data
not shown). Micelle encapsulation decreased cytotoxicity of the combination therapy
compared to free drug (Figure 3-4E and F) in DU145-TXR and PC3-TXR cell lines,
possibly due to slow drug release from the micelles. To summarize the drug loading
and release issues, PEG-PCD micelle might be a potent drug delivery system for in
vivo PTX and rubone delivery.
Table 3-2 Characterization of PTX and rubone formulation

Copolymer

Size (nm)

PDI

PEG-b-PCD (Blank)

136.50±1.40

0.208±0.010

PEG-b-PCD (PTX)

132.00±0.72

0.211±0.021

PEG-b-PCD (Rubone)

150.30±1.43

0.200±0.015
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Figure 3-4. Characterization of PEG-PCD micelles.
PTX and rubone loading of DSPE-PEG, PEG-PLA, and PEG-PCD were measure by
HPLC using standard curve of PTX and rubone. PTX and rubone loading were
summarized in A and B for PTX and rubone, respectively. PTX (C) and rubone (D)
release profile in single drug loaded micelles or PTX and rubone loaded micelles were
determined by HPLC. The effect of PEG-PCD encapsulation on drug toxicity was
determined in DU145-TXR (E) and PC3-TXR (F) cell lines.
3.3.5. PEG-PCD micellar formulation of PTX and rubone suppressed PTX-resistant
prostate tumor growth in vivo
To monitor the tumor growth and metastasis in the orthotopic prostate cancer
bearing nude mice, we first transduced PC3-TXR cell line with lentivirus expressing
both GFP and luciferase. After injecting the cells into dorsal prostate lobe, tumor
development was monitored by intraperitoneally injecting luciferin and recording body
weight every week. The presence and location of prostate tumor was shown in Figure
3-5A. Tumor fluorescence at 7th week in PTX and rubone combination therapy group
was significantly lower than the other three groups (Figure 3-5B). The tumor inhibitory
effect was also demonstrated by weekly monitoring the luminescence (Figure 3-5C),
which indicating the suppressed tumor growth in combination therapy group. This
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orthotopic prostate cancer mouse model is very aggressive so that we observed 20%
body weight loss during the treatment, while PTX and rubone formulation therapy had
little effect on body weight loss, suggesting the inhibition of tumor growth in
combination therapy group (Figure 3-5D). Finally, all the mice were sacrificed to isolate
the tumor for mearing the size (Figure 3-5E), which suggest significant tumor
suppressing effect of PTX and rubone formulation. miR-34a in tumor was significantly
upregulated with rubone alone or combined with PTX treatment (Figure 3-5F). To
further demonstrate the anticancer mechanism of rubone in vivo, we isolated the tumor
and determined cell proliferation marker and miR-34a downstream targets expression
(Figure 3-6). Rubone alone or with PTX significantly reversed E-cadherin, Cyclin D1,
and SIRT1 expression. Rubone monotherapy failed to suppress tumor cell proliferation
as indicated by Ki-67 staining, whereas PTX and rubone combination therapy
significantly suppressed tumor cell growth compared to PTX monotherapy. We further
determined TAp73 and Elk-1 expression in tumor tissue. Rubone alone or combination
therapy with PTX significantly upregulated TAp73 and Elk-1 expression. These data
indicated that rubone upregulated miR-34a expression in p53 independent pathways
in vivo. Collectively, our results demonstrated that rubone is a potent small molecule
miR-34a modulator to reverse the chemoresistance of advanced androgen-refractory
prostate cancer and enhance the therapeutic effect of PTX.
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Figure 3-5. Anti-tumor efficacy of PTX and rubone combination therapy.
Orthotopic prostate cancer model was generated using luciferase expressed PC3-TXR
cell line. Drug formulation was injected every two days after 3 weeks. A. Location of
orthotopic tumor generated from PC3-TXR cell. B. In vivo tumor luminescence was
determined by intraperitoneal injection of luciferin (120 mg/kg). C. Body weight of mice
in each group. D. miR-34a expression in tumor was determined by RT-PCR. E.
Bioluminescence and size of tumors in each group after 7 weeks.
3.4. Discussion
Drug resistance remains the major challenge of cancer chemotherapy even
with the discovery of highly efficient anticancer compounds. Furthermore, the skeletal
metastasis in advanced prostate cancer patients is the major cause of morbidity and
mortality(161). Tumors are composed of bulk cancer cells and small population of
CSCs, which are not responsive to most chemotherapeutic agents and result in
chemoresistance and tumor recurrence(162). In recent years, miR-34a was found to
inhibit CSC growth, metastasis, and chemoresistance by directly repressing the
adhesion molecule CD44(87). The downstream targets of miR-34a, including
SIRT1(163), LEF1(164), TCF7(165), AR, and Notch-1(166), are crucial factors of
proliferation, metastasis, and chemoresistance of advanced androgen-refractory
prostate cancer. Furthermore, our data indicated that miR-34a is significantly
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downregulated in the progress of prostate cancer, especially in PTX resistant cells
(Figure 3-1A). Thus, miR-34a replenishment by systemic delivery using nanoparticles
can therefore be developed as a potent therapeutic strategy. However, the off-target
effects, in vivo degradation, low efficacy and high cytotoxicity associated with drug
delivery systems of miRNA oligonucleotide still need to be overcome for miRNA based
clinical therapy.

Figure 3-6. Mechanism of miR-34a regulation in vivo. E-cadherin, Ki-67, cyclin
D1, SIRT-1, Tap73, and Elk-1 expression after PTX and rubone formulation
therapy was determined by IHC (Scale bar, 200 μM for backward figure and 50
μM for enlarged figure).
Recently, there are several researches showing small molecular as oncogenic
miRNA inhibitor(67, 70) and tumor suppressor miRNA modulator(68) for the inhibition
of tumor growth. Among these small molecules, retinoic acid(90), genistein(167), and
rubone(68) have been reported to upregulate miR-34a expression in several types of
cancer with the mechanism not well characterized. Traditional chemotherapy uses
PTX or docetaxel as a monotherapy for inhibiting cancer cell growth, which always fails
due to the chemoresistance caused by downregulation of tumor suppressor miRNA.
In this study, we present an alternative strategy for fighting PTX resistant prostate
cancer through miR-34a upregulation by employing a combination therapy using
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rubone as a small molecule miR-34a modulator. Our data suggest that rubone is nontoxic to normal prostate cells, whereas is highly toxic to PTX resistant prostate cancer
cells, which have low miR-34a expression (Figure 3-1B). For combination therapy with
PTX, rubone can reverse the chemoresistance of prostate cancer at low concentration
(5 μM). At this concentration, rubone significantly enhanced the cytotoxicity of PTX in
PTX-resistant prostate cancer cell lines, whereas did not influence the anticancer effect
of PTX in non-resistant cell lines. Extracellular matrix is key regulator of homeostasis
and tissue phenotype to form 3D culture assays(168), which allows the phenotypic
discrimination between nonmalignant and malignant mammary cells. Since some
crucial signals are lost when cells are cultured in vitro on 2D plastic flasks(150), 3D
model could better mimic the in vivo tumor environment and evaluate the anticancer
effect of therapeutic agents. Thus, we determined the anti-tumor efficacy of PTX and
rubone combination therapy in 3D model (Figure 3-2G and H), where 3D on top allows
the tumor to grow on extracellular matrix (Matrigel) and hanging-drop model can help
tumor cell form sphere-like structure without Matrigel. PTX and rubone combination
therapy inhibited tumor cell growth and disturbed tumor morphology in 3D models.
These data indicated that rubone can work as a non-toxic, highly specific miR-34a
modulator to enhance the therapeutic effect of PTX.
Previous report claimed that rubone inhibits HCC growth in a p53 dependent
manner(68). In that research, rubone has no therapeutic effect in Hep3B cells, which
does not express p53. Interestingly, our results showed that rubone significantly
reversed miR-34a and its downstream target gene expression in p53-null PC3-TXR
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cells (Figure 3-2E and J). Furthermore, rubone enhanced the therapeutic effect of
PTX, inhibited the metastasis, and decreased the population of CSC in PC3-TXR cells
(Figure 3-3A-E), suggesting that rubone might upregulate miR-34a in a p53
independent pathway. Therefore, we analyzed TAp73(90, 158) and Elk-1(159, 160)
expression, which are previously reported to be p53 independent miR-34a regulation
pathway. Our data showed that TAp73 and Elk-1 were highly upregulated after rubone
monotherapy or PTX and rubone combination therapy (Figure 3-3F and G). This
discrepancy may be explained by the extremely low expression of TAp73(169) and
Elk-1(170) in Hep3B cells compared to PC3-TXR cells, which means that all known
miR-34a regulation pathways are blocked in Hep3B cells. Thus, we conclude that
rubone might work as a miR-34a modulator for prostate cancer in a p53 independent
manner.
Polymeric micelles can increase aqueous solubility of hydrophobic drugs
thereby avoiding the use of toxic solubilizing agents, including DMSO and Cremophor
EL. In this study, we synthesized PEG-PCD lipopolymer, which allows the conjugation
of multiple lipid chains to a polycarbonate backbone for the optimization of drug loading.
The pendant lipid groups in the lipopolymers could increase the interaction of
hydrophobic drugs with the core, improve in vivo micelle stability, and prolong
circulation half-life. Thus, we compared the drug delivery property of our PEG-PCD
with two commercially available polymers PEG-PLA and DSPE-PEG. PEG-PCD has
higher PTX and rubone loading compared to PEG-PLA and DSPE-PEG, especially
when loading both drugs (Figure 3-4A and B). The decreased drug release was
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observed when loading both drugs, indicating drug-drug interaction in the same drug
delivery platform could influence the drug delivery property.

Figure 3-7. Illustration of rubone working as a miR-34a modulator for combination
therapy with PTX.
The anticancer efficiency was evaluated in an orthotopic prostate tumor model to
mimic the clinical condition and monitor tumor growth in a non-invasive manner. Tumor
growth was significantly suppressed after systemic administration of PTX and rubone
formulation compared to other three groups according to the luminescence at each
time point (Figure 3-5C) and the tumor size at the end of the study (Figure 3-5E). Our
data also indicated that PTX and rubone combination therapy reversed the
downstream target genes of miR-34a through TAp73 and Elk-1 pathways (Figure 36). However, this orthotopic model using PC3-TXR cell line was very aggressive since
we observed severe body weight loss in the progress of tumor (Figure 3-5D) and few
mice could survive for more than 7 weeks without treatment. Under this severe
condition, PTX and rubone combination therapy showed promising therapeutic effect
by suppressing the tumor growth and avoid body weight loss.
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3.5. CONCLUSION
Based on our results, rubone could be a specific miR-34a regulator to reverse
miR-34a and the downstream target gene expression for PTX resistant prostate cancer
(Figure 3-7). The replenished miR-34a promoted the anticancer effect of paclitaxel on
microtubule disarray, which promotes cell apoptosis and inhibits proliferation.
Moreover, this miR-34a replenishment by rubone is in a p53 independent manner in
DU145-TXR and PC3-TXR cell lines. PTX and rubone combination therapy formulated
by PEG-PCD micelles could significantly suppress PTX resistant tumor growth in vivo.
This study illustrated a new therapeutic potent of rubone as a small molecule miR-34a
modulator for the treatment of PTX-resistant prostate cancer. Rubone might work with
PTX in clinical for chemotherapy to avoid chemoresistance and enhance the
therapeutic effects.
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CHAPTER 4. MESENCHYMAL STEM CELL AND DERIVED EXOSOMES AS
SMALL RNA CARRIER AND IMMUNOMODULATOR TO IMPROVE ISLET
TRANSPLANTATION
4.1. INTRODUCTION
Type 1 diabetes, which comprised of 5-10% of the total diabetic population, might
be treated by islet transplantation. Despite recent therapeutic success, the wide
application of islet transplantation is still limited due to the destruction and dysfunction
of transplanted islets caused by immune rejection and loss of islet function, which is
characterized as primary non-function (PNF)(106). The major mechanisms behind
these two processes are proinflammatory cytokines triggered apoptosis and hypoxia
related proteins or miRNAs expression, including Fas, Caspase-3, iNOS, and miR375(171-174). As a potent approach for inhibiting aberrant protein and miRNA
expression, RNA interference (RNAi) by short interfering RNAs (siRNAs) or antimiRNAs is becoming a promising tool. However, its efficacy is greatly influenced by
RNA degradation, poor cellular uptake, and rapid renal clearance after systemic
administration(175). Thus, expression vectors are being developed for efficient siRNA
delivery or simultaneously silencing multiple genes. Bain et al. first reported the
feasibility of islet RNA delivery using adenovirus.(176) Nevertheless, the application of
viral vectors is limited due to the potential of insertional mutagenesis and/or severe
immune reaction.(177, 178) In contrast, cationic lipids or lipid-like vesicles are relatively
safe as small RNA carriers due to their low cytotoxicity, high versatility, and target
specificity by surface modification. However, cationic liposomes have low transfection
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efficiency in intact human islets, especially when used for delivering plasmid DNA.(109)
Therefore, to develop a suitable and effective small RNA delivery system might help
transplanted islets survive from immune rejection and PNF process and further
improve the outcome of islet transplantation.
Secreted membrane vesicles have attracted much interest because of their
potential as biomarkers of diseases, therapeutic agents, and vehicles for drug
delivery.(179) Among these vesicles, exosomes (30-100 nm) are natural nano-vesicles
secreted by numerous cell types.(116) They have a bi-lipid membrane and cargos
including mRNAs, miRNAs, and proteins, which can be transferred and thus affect the
protein production of recipient cells.(180) As a novel RNA delivery vehicle, exosomes
have high delivery efficacy as they can circumvent endocytosis(181) and escape rapid
clearance by the cells of reticuloendothelial system.(182) Previous research indicated
that exosomes derived from genetically modified dendritic cells or mesenchymal stem
cells (MSCs) can deliver siRNA or miRNA to the mouse brain(116) or cancer cells to
inhibit glioma growth.(117) Compared with other cells, hBMSCs might be a more
suitable source of exosomes for improving islet transplantation due to their selfrenewal potential(183) and immunosuppressive effects(184). Furthermore, some of
tissue repair(185) and immunosuppressive properties(186) of MSCs have been
reported to be transferred to MSC-derived exosomes. Early studies showed that
endothelial

progenitor

cell-derived

microvesicles/exosomes

enhanced

neoangiogenesis of human islets,(187) while umbilical cord blood MSC-derived
microvesicles suppressed peripheral blood mononuclear cell (PBMC) proliferation in
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vitro.(188) However, the neoangiogenesis and immunosuppressive effect of hBMSCderived exosomes to improve islet transplantation and their small RNA delivery
potential to human islets remain largely unknown.
In the present study, we utilized hBMSCs and their exosomes to suppress islet
apoptosis and PNF at the acute stage (<2 weeks) of islet transplantation by codelivering siRNA against Fas receptor (siFas) and miR-375 inhibitor (anti-miR-375).
The inhibition of the post-transplanted immune reaction is further achieved by
intravenously injecting hBMSC and PBMC co-cultured exosomes. Our model enabled
reversal of diabetes without a need of insulin injection and proved the clinical potential
of hBMSC and its exosome-based small RNA delivery and immunotherapy method to
improve the outcome of islet transplantation.
4.2. MATERIAL AND METHODS
4.2.1. Cell Culture and Exosome Isolation.
Rat insulinoma (INS-1E) cells, a kind gift from Professor Claes B. Wolheim
(University Medical Center, Geneva, Switzerland) were cultured in RPMI 1640
containing 10% FBS, 1% sodium pyruvate, and 50 μM 2-mercaptoethanol. Human
islets were received from Integrated Islet Distribution Program (USA) and cultured in
CMRL-1066 medium containing 10% FBS. Primary hBMSCs, which was characterized
previously(189), were purchased from Celleng-tech (Coralville, IA) and cultured in
HyClone Advanced Stem Cell Medium and exosome-depleted FBS. Plasmid
transfected hBMSCs were characterized for adipogenic/osteogenic differentiation
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using oil red o/alizarin red staining. In transwell system, 5×104 plasmid tranfected
hBMSCs were adherent at a 0.4-μm transwell cell culture insert, while 2000 islet
equivalents (IEQs) were cultured outside in a 6-well plate. hBMSCs in all experiments
were cultured for less than 3 passages to avoid differentiation. PBMCs were received
from Dr. Howard Gendelman’s lab at the University of Nebraska Medical Center and
further cultured in medium composed of RPMI 1640 and 10% FBS. hBMSC-derived
exosomes were isolated from 50-70% confluent hBMSC culturing media, while hBMSC
and PBMC co-cultured exosomes were isolated from co-cultured media incubating 5070% confluent hBMSCs and 106 PBMCs/mL for 48 h using total exosome isolation
reagent (Invitrogen). Co-cultured media was obtained from a T25 flask containing 105
hBMSCs and 5×106 PBMCs after co-culturing for 2 days.
4.2.2. Cloning, Transfection, RNA Isolation, and Real Time RT-PCR.
shFas and anti-miR-375 sequences were cloned into BbsI/BbsI and Acc65I/HindIII
sites of psiRNA-DUO vector (InvivoGen). Lipofectamine 2000 and Xfect transfection
reagents (Clontech) were used to transfect INS-1E cells and hBMSCs, respectively.
RNA was isolated from hBMSC-derived exosomes using total exosome protein & RNA
isolation kits (Invitrogen). RNeasy and miRNeasy mini kits were used to extract mRNA
and miRNA from INS-1E cells and human islets. For exosome RNA, 5 μL RNA
extraction products were converted to cDNA. β actin, U6, and total protein
concentration were used as internal controls for cellular mRNA, miRNA, and exosome
miRNA, respectively.

89

4.2.3. Exosome and RNA Uptake Study.
hBMSCs were incubated with DiI-C16 (3 μM) for 1 h. Then, hBMSCs were washed
three times with 37oC PBS, trypsinized and incubated with 100 islets in the transwell
system for 48 h. To determine siRNA transferring, hBMSCs were transfected with Alexa
Red conjugated siRNA for 24 h and incubated with human islets for another 48 h.
Lipofectamine 2000 and Xfect transfection reagent were used as negative control
following the user’s protocol. shFas-Spinach was cloned into Acc65I/HindIII of psiRNAh7SKzeo vector (InvivoGen) and further transfected to hBMSCs, which was cocultured with human islets and non-transfected hBMSCs in a transwell system. Before
Spinach aptamer imaging, culturing media was replaced with imaging media (DMEM
without phenol red or vitamins and contained 25 mM HEPES, 5 mM MgSO4, 50 mM
KCl, and 20 μM 3,5-difluoro-4-hydroxybenzylidene imidazolinone (DFHBI, Lucerna))
and incubated for 30 min. To determine the endosome uptake of exosome delivered
small RNA, early endosome and lysosome were labelled by the lysotracker (Thermo
Scientific).
4.2.4. Cell and Islet Viability Study.
After transfection with Lipofectamine/siRNA complexes for 48 h, INS-1E cells were
treated with streptozotocin (STZ, 0.2 mM dissolved in 0.1 M citrate buffer) for 6 h,
followed by analyzing living cells using fresh medium containing 0.5 mg/mL 3-(4,5Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT). After co-culturing with
plasmid transfected hBMSCs for 72 h, islet/hBMSC co-culture was stimulated with
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cytokine cocktail (5 μg/mL IL-1β, 50 ng/mL TNF-α, and 50 ng/mL IFN-γ) for another 4
days, followed by 5 μg/mL calcein AM and 2 μg/mL propidium iodide staining for 30
min. Islet apoptosis was evaluated under fluorescent microscope and quantified by
flow cytometry using Alexa Fluor Annexin V/PI staining kit (Invitrogen).
At 48 h after transfection, insulin release of INS-1E cells responding to glucose
stimulation was quantified by stimulating INS-1E cells with Krebs-Ringer bicarbonate
(KRB) buffer containing basal (2.5 mM) and stimulated (22 mM) glucose for 1 h. To
better study the reaction of human islets with glucose stimulation, insulin secretion
from human islets was quantified using a dynamic islet perifusion assay. Briefly, 50
handpicked islets were loaded onto a Swinnex 13 chamber (Millipore, Burlington, MA)
and perfused with KRB buffer containing basal (1.67 mM) or stimulated (16.7 mM)
glucose. The temperature was maintained at 37oC and the flow rate was maintained
at 1 mL/min. Islets were first perifused with basal glucose for 60 min and stimulated for
30min, followed by perifusing with basal glucose till insulin reverse to the basal level.
Samples were collected every 2 min and analyzed for insulin concentration by ELISA.
4.2.5. Mixed Lymphocyte Reaction.
PBMCs were first labeled with carboxyfluorescein succinimidyl ester (CFSE) and
treated with hBMSC-derived exosomes or hBMSC and PBMC co-cultured exosomes
(150 μg/mL protein concentration). To optimize the immunosuppressive effect of
hBMSC and PBMC co-cultured exosomes, exosomes were isolated from co-culturing
media with the ratio of hBMSC: PBMC=1:5, 1:10, 1:25, and 1:50 with 1×105 hBMSCs.
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PBMCs were then stimulated with phytohaemagglutinin (PHA) (5 μg/mL) and cultured
for another 7 days before flow cytometry analysis. IL-2, IFN-γ, and IL-2sRα in medium
and IL-10, PGE-2, TGF-β, VEGF, and HGF in exosomes were determined by ELISA.
For analyzing Tregs population, CD4+ cells were first isolated and the population of
CD25+FoxP3+ among total CD4+ cells were determined by flow cytometry using human
regulatory T cells 3 color kit (R & D systems). miR155, miR-let7b, miR-let7d in medium
exosomes were determined by RT-PCR. For in vivo study, NSG mice were humanized
by intraperitoneally infusion of PBMCs (5×106/mouse) and co-cultured exosomes (10
mg/kg) were intravenously injected every other day, followed by immunohistochemical
(IHC) staining of CD3 and determining blood serum IgG concentration by ELISA.
4.2.6. Islet Transplantation.
NSG mice were purchased from Jackson Laboratory and bred in-house in
accordance with a protocol approved by the Institutional Animal Care and Use
Committees of the UNMC. STZ (70 mg/kg) was injected intraperitoneally to NSG mice
every two weeks until diabetes was induced. Animals were considered diabetic as
indicated by two consecutive measurements of blood glucose ≥ 250 mg/dl. Then, 2000
IEQs were co-transplanted with primary hBMSCs, pshFas transfected hBMSCs, pantimiR-375 transfected hBMSCs, and pshFas-anti-miR-375 transfected hBMSCs at the
ratio of islet: hBMSC= 1:25 (2000 IEQ and 50000 hBMSCs) under the kidney capsule,
followed by PBMCs (5×106/mouse) intraperitoneal infusion four weeks after islet
transplantation as described previously.(189, 190) Two weeks after humanization, cocultured exosomes were injected intravenously in randomly selected 10 mice receiving
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islets co-transplanted with pshFas-anti-miR-375 transfected hBMSCs. Three months
after islet transplantation, immune rejection and transplanted islets function were
evaluated by serum insulin & IgG concentration, followed by intraperitoneal glucose
tolerance study. Briefly, overnight fasted mice were subjected to intraperitoneal
injection of glucose (2 g/kg). Blood glucose level was determined at 15, 30, 60, 90,
120, and 180 min.
4.2.7. Western Blot Analysis and Immunofluorescence Staining.
INS-1E cells protein was extracted using RIPA buffer after transfection for 48 h.
The amount of protein was adjusted to the same concentration and incubates with
primary and secondary antibodies, followed by Licor Odyssey system analysis.
To analyze in vivo small RNA delivery efficacy and immunosuppressive effect of
hBMSCs and exosomes, mice were sacrificed 1 week or 3 months after islet
transplantation. Kidney bearing islets or spleens were isolated, washed with PBS, fixed
in 4% paraformaldehyde overnight and embedded in paraffin. The tissue slides were
further stained by anti-Fas and anti-Mtpn primary antibodies for kidney and anti-CD3
primary antibody for both kidney and spleen. Protein expression was determined by
incubating tissue slides with secondary antibodies. The following primary antibodies
were used for western blotting and IHC staining: anti-Fas (Abcam, ab82419), anti-Mtpn
(Sigma-Aldrich, HPA019735), anti-CD3 (Abcam, ab16669), anti-insulin (Abcam,
ab7842), anti-Beta actin (Santa Cruz, sc-1616).
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4.2.8. Statistical Analysis.
Results were presented as mean ± s.e.m. from three experiments for in vitro study
and five experiments for in vivo study. The statistical significance of difference between
the two groups was calculated by unpaired Student’s t-test, and a P < 0.05 was
considered to be statistically significant.
4.3. RESULTS
4.3.1. pshFas-anti-miR-375 Improved Cell Viability and Insulin Release of Rat
Insulinoma Cells
Fas/FasL pathway plays an important role in β-cell apoptosis in type 1 diabetes,
especially in high glucose condition.(172) miR-375, which also contributes to normal
pancreatic islet formation(191), has been reported to downregulate insulin secretion
by acting on myotrophin (Mtpn)(108) and PDK1(192). For Fas silencing, two siFas
sequences (siRNA 175 and siRNA 480) were selected, of which siRNA 480 showed
better Fas silencing, anti-apoptotic and insulin promotion effect (Data not shown).
Mtpn, the target protein of miR-375, was upregulated and insulin release was
significantly enhanced after anti-miR-375 transfection (Data not shown). Then, siRNA
480 or siFas for human islets and anti-miR-375 sequences were cloned into psiRNADUO vector (Figure 4-1A). pshFas-anti-miR-375 transfected INS-1E cells showed
better anti-apoptotic effect and insulin release compared to pshFas and panti-miR-375
transfected cells (Figure 4-1B and C).
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Figure 4-1. Fas and miR-375 were silenced by hBMSC-derived exosomes
delivered siFas and anti-miR-375.
(A) Outline of pshFas-anti-miR-375 construction. (B) pshFas-anti-miR-375 improved
INS-1E viability against STZ. (C) pshFas-anti-miR-375 improved insulin release of
INS-1E cell line. Exosomes were then isolated from pshFas, panti-miR-375, or pshFasanti-miR-375 transfected hBMSC media. siFas (D) and anti-miR-375 (E) were highly
overexpressed in plasmid transfected hBMSC-derived exosomes determined by RTPCR. pshFas, panti-miR-375, and pshFas-anti-miR-375 transfected hBMSCs were cocultured with human islets in a transwell system for 72 h. Fas (F) and miR-375 (G) of
human islets were significantly downregulated after co-culturing with plasmids
transfected hBMSCs in the transwell system
4.3.2.

pshFas-anti-miR-375

Transfected

hBMSC-derived

Exosomes

Downregulated Expression of Fas and miR-375 in Human Islets.
The adipogenic/osteogenic differentiation of hBMSC was characterized by oil red
o/alizarin red staining. 3 passages hBMSCs did not have adipogenic/osteogenic
differentiation, whereas hBMSCs over 10 passages might differentiate into adipocyte
or osteocyte (Data not shown). To evaluate small RNA delivery potential of hBMSCderived exosomes to human islets, hBMSCs were first transfected with pshFas, pantimiR-375, pshFas-anti-miR-375, or scramble plasmid using Xfect transfection reagent.
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Transfection efficacy was evaluated by GFP expression. Our results showed
significantly elevated levels of siFas (Figure 4-1D) and anti-miR-375 (Figure 4-1E) in
exosomes after transfection for up to six days. Furthermore, pshFas and pshFas-antimiR-375 transfected hBMSCs downregulated Fas expression by 53.4% and 46.9%
(Figure 4-1F) while miR-375 was downregulated by 69.84% and 55.88% (Figure 41G) after co-culturing islets with panti-miR-375 and pshFas-anti-miR-375 transfected
hBMSCs, respectively. These results suggest that hBMSCs could deliver small RNAs
to human islets by secreting mediators without direct touch.
In previous studies, hBMSCs were proven to deliver siRNA to cancer cells(193)
and neuron cells(194) by direct touch and hBMSC-derived exosomes. We first showed
that hBMSC-derived exosomes were efficiently taken up by human islets after 48 h
(Figure 4-2A). Moreover, our results (Figure 4-2B) proved siRNA can be delivered to
human islets from hBMSCs by direct touch and exosomes. Lipofectamine 2000 and
Xfect transfection reagent was used as control to evaluate siRNA delivery efficacy of
hBMSC to human islets. Our results indicated that hBMSC has higher siRNA delivery
efficacy compared to lipid-like polymers (Figure 4-2B). We further linked the Spinach
aptamer, which was first reported by Paige et al. as an RNA mimic of GFP and fused
to the 3’ end of 5S rRNA to localize this small noncoding RNA,(195) to shFas (Fig. 2F
and G) and co-cultured shFas-Spinach plasmid transfected hBMSCs (Figure 4-2C)
with human islets for 48 h. Our results (Figure 4-2D) showed that plasmid generated
shFas-Spinach RNA aptamer from exosome donating cells (hBMSCs) could be
delivered to human islets as recipient cells. Furthermore, endocytic cycling could be

96

circumvented by exosome delivery (Figure 4-2E). For the feasibility of monitoring the
location of Spinach aptamer, we selected hBMSCs rather than human islets as
recipient cells. Collectively, our results showed that hBMSC-derived exosomes and
contained siRNAs or shRNAs generated from exosome donating cells can be taken up
by human islets.

Figure 4-2. Small RNAs delivered by hBMSC-derived exosomes can be
efficiently taken up by human islets and circumvent endosome degradation.
(A) In a transwell system, hBMSC-derived exosomes can be taken up by human islets
after 48 h. (B) siRNAs were delivered from hBMSCs to human islets by direct touch
and exosome. shFas-Spinach aptamer can be expressed in hBMSCs (C) and further
transferred to human islets in the same transwell system after 48 h (D). Arrows indicate
exosome loaded shFas-Spinach aptamer. (E) For the feasibility of identifying the
location of shFas-Spinach aptamer, hBMSC was selected as the recipient cell to
determine the delivering efficacy. Exosome delivered shFas-Spinach aptamer
circumvent endosome process. (F) 2D structure of shFas-Spinach. (G) 3D structure of
shFas-Spinach.
4.3.3. pshFas-anti-miR-375 Transfected hBMSC-derived Exosomes Inhibited Islet
Apoptosis and Improved Islet Function Against Inflammatory Cytokines.
Recruited T cells at the transplantation site cause the major loss of islet grafts by

97

stimulating an immune response or secreting inflammatory cytokines, which can
upregulate Fas expression on β cells, thus activating Fas signaling.(196, 197)
Therefore, we determined the protection effect against inflammatory cytokines from
plasmid transfected hBMSC-derived exosomes in the transwell system. After
stimulating with cytokine cocktails (5 ng/mL IL-1β, 50 ng/mL TNF-α, and 50 ng/mL IFNγ) for 4 days, islets co-cultured with pshFas-anti-miR-375 transfected hBMSCs showed
better viability compared to other three groups determined by Calcein AM/PI staining
and quantified by flow cytometry using Annexin V/PI kit (Figure 4-3A-D). We also
indicated that islets co-cultured with pshFas, panti-miR-375, and pshFas-anti-miR-375
transfected hBMSCs all showed improved insulin release in different extension in both
basal (1.67 mM) and stimulated (16.7 mM) stage while pshFas-anti-miR-375 showed
higher insulin release at each time point and accumulative amount compared to other
groups (Figure 4-3E and F). Our results showed that cytokine cocktails challenging
suppressed 30.5% insulin release compared to non-treatment group (Figure 4-3F
hBMSC vs Fig. 3H hBMSC), which was in accordance with our previous report.(189)
We observed 3.88 times accumulative insulin release from Fas and miR-375 silenced
islets compared to hBMSCs co-cultured islets (Figure 4-3F). Even though cytokine
cocktail treatment suppressed insulin release in each group (Figure 4-3H), pshFasanti-miR-375 transfected hBMSCs significantly prevented islet impairment (Figure 43G), suggesting protective effect from silencing Fas and miR-375.

98

Figure 4-3. pshFas-anti-miR-375 transfected hBMSCs suppressed islet
apoptosis and improved islet function against cytokine cocktail.
pshFas (B) and pshFas-anti-miR-375 (D) transfected hBMSCs efficiently suppressed
islet apoptosis caused by cytokine challenging compared to non-transfected (A) and
panti-miR-375 transfected (C) hBMSCs. Cumulative insulin release was calculated
from dynamic insulin release profile. (E) no cytokine treated. (F) cumulative insulin
release without cytokine treated. (G) cytokine cocktail treated. (H) cumulative insulin
release with cytokine cocktail treated.
4.3.4. hBMSC and PBMC Co-cultured Exosomes Suppressed Activation and
Proliferation of PBMCs.
Previous reports showed that hBMSC and PBMC co-cultured media exhibited
stronger immunosuppressive effect compared to hBMSC media.(198) We first showed
that hBMSC and PBMC co-cultured exosomes suppressed PBMC proliferation by
CFSE staining (Data not shown). To optimize the immunosuppressive effect of
hBMSC and PBMC co-cultured exosomes, we isolated exosome from co-cultured
media with the ratio of hBMSC and PBMC 1:5, 1:10, 1:25, and 1:50. The
immunosuppressive effect of co-cultured exosomes exhibited a dose-dependent
manner with the increased number of PBMC (Data not shown). Co-cultured
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exosomes inhibited PBMC activation as indicated by significant decrease of IL-2, IFNγ, IL-2sRα concentrations in the medium (Data not shown). To work out the
immunomodulatory mechanism of exosomes (Figure 4-4A), our results indicated that
HGF played an important role in exosome-mediated immunomodulatory effect of
hBMSCs (Figure 4-4B), while IL-10, VEGF, PGE-2, and TGF-β showed moderate
effect (Data not shown). When PHA stimulated PBMCs were co-cultured with hBMSC
and PBMC co-cultured exosomes or hBMSCs, the population of Tregs was increased
from 4.9 to 7.0-8.7% (Figure 4-4C). Different from our results, previous research
indicated that MSC-derived exosomes increased the population of Tregs(188),
because the sources of MSCs in these studies were different. Okoye et al.(199)
reported that Tregs suppressed pathogenic T helper 1 cells by regulating miR-155,
miR-let7b, and miR-let7d in Tregs derived exosomes. Compared to hBMSC-derived
exosomes, our results showed that hBMSC and PBMC co-cultured exosomes more
significantly enhanced the expression of miR-let-7b and miR-let-7d (Figure 4-4D),
which were reported to suppress cell proliferation and induce apoptosis.(200)
Furthermore, co-cultured exosomes downregulated miR-155 expression (Figure 44D), which enhances inflammatory T cell development and promotes autoimmune
inflammation.(201) It was previously reported that CD14+ cells among PBMCs were
responsible for IL-10 related immunosuppression.(189) However, our results indicated
that crosstalk between hBMSC and PBMC did not influence IL-10 secretion. Moreover,
similar to PGE-2, most IL-10 was directly secreted into medium after PHA stimulation,
rather than through exosomes. Thus, IL-10 and PGE-2 might work more specifically in
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PBMC activated condition, where both factors were highly secreted in media (Data not
shown).

Figure 4-4. Immunosuppressive mechanisms and in vivo immunosuppressive
effect of hBMSC and PBMC co-cultured exosomes.
(A) The outline of crosstalk between hBMSC and PBMC. (B) HGF concentration in
exosome and media after co-culturing PBMC with hBMSC or PHA activation. (C)
hBMSC-derived exosomes enhance Tregs population. (D) hBMSC-derived exosomes
enhanced Tregs-derived miR-let7b and miR-let7d concentration and downregulated
miR-155 concentration.
To evaluated immunosuppressive effect in vivo, our results showed that hBMSCderived exosomes were accumulated in the liver, spleen, and kidney (Figure 4-5A).
hBMSC and PBMC co-cultured exosomes significantly suppressed PBMC activity
determined by spleen CD3 staining (Fig. 4-5B-D) and serum IgG concentration
(Figure 4-5E), whereas hBMSC-derived exosomes had moderate immunosuppressive
effect. In summary, our results indicated that hBMSC and PBMC co-cultured exosomes
might be a potent immunosuppressive regimen for inhibiting immune rejection in vitro
and in vivo.
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Figure 4-5. Immunosuppressive effect of exosome in vivo.
(A) Biodistribution of DiI-C16 labeled exosomes. In vivo T cell activity was determined
by spleen CD3 staining after i.v. injection of saline (B), hBMSC-derived exosomes (C),
and hBMSC & PBMC co-cultured exosomes (D). E: T cell activity was also determined
by serum IgG level.
4.3.5. pshFas-anti-miR-375 Transfected hBMSCs Combined with hBMSC and
PBMC Co-cultured Exosomes Improved Islet Survival in Humanized NSG Mice.
The procedure of our animal surgery was summarized in Figure 4-6A. We
evaluated the in vivo gene delivery efficacy by co-transplanting plasmid transfected
hBMSCs and human islets in kidney capsule and allow them to settle down for 4 weeks,
followed by intraperitoneal injection of PBMC for mimicking the post-transplanted

102

immune rejection. In a humanized NSG mouse model, non-transfected hBMSCs failed
to prevent acute stage apoptosis of islets after transplantation (Figure 4-6B, 30%
insulin independence). Both pshFas and panti-miR-375 improved transplanted islets
survival (Figure 4-6C and D, 50 and 60% insulin independence, respectively), while
pshFas-anti-miR-375 significantly suppressed apoptosis by 90% (Figure 4-6E). After
PBMC perfusion, pshFas or panti-miR-375 transfected hBMSCs failed to maintain
normal blood glucose level after three months compared to pshFas-anti-miR-375
transfected hBMSCs (10 and 30% vs. 60% insulin independence). However,
intravenous injection of hBMSC and PBMC co-cultured exosomes significantly
suppressed immune rejection after humanization of the mice receiving islets cotransplanted with pshFas-anti-miR-375 transfected hBMSCs (Figure 4-6F, 100%
insulin independence). Our results also showed that insulin content of mice receiving
islets co-transplanted with pshFas, panti-miR-375, and pshFas-anti-miR-375
transfected hBMSCs was significantly higher than those received islets cotransplanted with non-transfected hBMSCs (Figure 4-6H and I). pshFas-anti-miR-375
transfected hBMSCs downregulated Fas (Figure 4-6H) and enhanced Mtpn (Figure
4-6I) expression in transplanted islets. In summary (Figure 4-6G), pshFas-anti-miR375 transfected hBMSCs combined with hBMSC and PBMC co-cultured exosomes
induced a totally insulin independence by inhibiting islet apoptosis, promoting islet
function, and suppressing immune reaction after humanization.
Three months after islet transplantation, hBMSC and PBMC co-cultured exosomes
significantly inhibited PBMC infiltration to transplanted islets and in vivo activity of
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PBMCs determined by CD3 staining (Figure 4-7A-C). Almost no detectable islets were
observed at the transplantation sites when co-transplanting with non-transfected
hBMSCs (Figure 4-7A). Although pshFas-anti-miR-375 transfected hBMSCs help
islets survive from acute stage apoptosis, islets were still undergoing apoptosis caused
by T cell infiltration (Figure 4-7B). However, transplanted islets were protected from T
cell infiltration in the mouse receiving hBMSC and PBMC co-cultured exosomes
(Figure 4-7C). In accordance with CD3 staining, serum IgG level was more
significantly decreased with increased insulin level after hBMSC and PBMC cocultured exosome administration compared to other four groups (Figure 4-7D). Our
results also showed that islets co-transplanted with pshFas-anti-miR-375 transfected
hBMSCs with or without exosome injection exhibited faster and better response to the
stimulatory glucose (2 g/kg) (Figure 4-7E). Taken together, these results suggest that
hBMSCs and their exosomes might be a potent vehicle for small RNA delivery to
human islets. hBMSC and PBMC co-cultured exosomes might work as bio-generated
immunosuppressive nanovesicles to inhibit further immune response of transplanted
islets. Our model for small RNA delivery and immune suppression might give clinical
prospect to improve the outcome of islet transplantation.
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Figure 4-6. pshFas-anti-miR-375 transfected hBMSCs combined with hBMSC
and PBMC co-cultured exosomes improve the outcome of islet transplantation.
(A) Outline of animal study procedure. For islet transplantation, islets were cotransplanted with hBMSC (B), pshFas transfected hBMSC (C), panti-miR-375
transfected hBMSC (D), pshFas-anti-miR-375 transfected hBMSC (E), and pshFasanti-miR-375 transfected hBMSC with intravenous injection of hBMSC and PBMC cocultured exosomes two weeks after humanization for four doses (F). Horizontal dotted
line indicated insulin independence. Vertical dotted line showed intraperitoneal
injection of PBMC to build human immune system. (G) Insulin independence was
summarized by the Kaplan-Meier plot. In vivo gene silencing effect of hBMSC and
hBMSC-derived exosomes were determined by IHC staining of Fas (H) and Mtpn (I),
downstream target of miR-375. Islet location was indicated by insulin staining.
4.4. DISCUSSION
Even though the Edmonton protocol has been developed for more than 20 years,
the application of islet transplantation is still limited due to the huge loss of islet mass
after transplantation. The immune rejection and PNF of islet grafts remains a challenge
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despite the development of new therapeutic regimens, which always induce organ
toxicity or severe side effects.(189) Compared with small molecules, hBMSCs can be
isolated from patient and infused back after in vitro gene modification with reduced
side effects impacting other organs and tissues.(202) Previous research showed that
systemic administration of MSCs prevented the onset of type 1 diabetes by engrafting
in injured tissue and differentiate to replace damaged cells.(203) However, only less
than 1% of transplanted MSCs were observed to reach the injured tissues with most
of them being trapped in the liver, lungs, and other organs.(204) Even in the case
where transplanted MSCs showed tissue repairing effect, engraftment and
differentiation of MSCs at the damaged site was low and transient,(205) suggesting
that MSCs exert most effect through secreted mediators.
Exosomes were first discovered in mature mammalian reticulocytes(206) as a role
of selectively removing plasma membrane proteins. Recently, two methods were used
to load drugs in exosomes: (i) mixing with exosomes and sucrose gradient
centrifugation for small molecules;(207) (ii) physical disruption(116) (electroporation)
or gene modification of original cells for nucleic acid. Gene modification is always
recommended for delivering nucleic acid due to the stability and aggregation issue in
electroporation process.(208) In our study, we obtained 672.3 and 407.0 times
overexpression of siFas after pshFas and pshFas-anti-miR-375 transfection (Figure
4-1D). Overexpression of anti-miR-375 was 24.3 and 14.2 times higher than control
groups after panti-miR-375 and pshFas-anti-miR-375 transfection (Figure 4-1E).
Significant discrepancy in expression level of two products might be explained by the
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specificity of different primers since the Cp value of siFas in the control group was
36.97 while anti-miR-375 was 26.69. Thus, the specificity of primer might be a crucial
issue for calculating the accurate amount of small RNAs inside exosome.

Figure 4-7. hBMSC and PBMC co-cultured exosome suppressed immune
rejection after islet transplantation.
Islets were co-transplanted with hBMSC (A), pshFas-anti-miR-375 transfected hBMSC
(B), and pshFas-anti-miR-375 transfected hBMSC followed by intravenous injection of
hBMSC and PBMC co-cultured exosomes two weeks after humanization (C). Three
months after islet transplantation, mice were sacrificed and immune activity was
determined by CD3 staining, while transplantation site was identified by insulin staining.
Immune rejection and transplanted islets function were evaluated by serum insulin &
IgG concentration (D) and intraperitoneal glucose tolerance study (E).
For intracellular function of Fas signaling, Schumann et al. reported Fas deficient
mice displayed impaired glucose tolerance and decreased insulin release(209) while
Feng et al.(210) and Choi et al.(211) claimed that decreased Fas activity reversed the
effect of c-Kit inactivation and enhanced insulin release. Similarly, the role of miR-375,
which is highly overexpressed in type 1 diabetes patient serum or transplanted
islets,(212, 213) is controversial as some groups reported that overexpression of miR-
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375 did not affect the development or function of islets,(214) whereas others reported
that forced miR-375 expression impaired cell proliferation and insulin secretion.(173)
According to our results, Fas gene silencing induced slightly enhanced insulin release.
(Figure 4-3E and F) Nevertheless, under the treatment of cytokine cocktail, Fas gene
silencing showed significant islet protective effect (Figure 4-3G and H), probably
because Fas/FasL interactions were one of the major mechanisms leading to β cell
apoptosis.(215) For miR-375, our results showed that suppressing miR-375
expression significantly enhanced insulin release at each time point (Figure 4-3E).
Islet apoptosis was significantly inhibited and insulin release was enhanced under
inflammatory cytokine treatment after simultaneously silencing Fas and miR-375
(Figure 4-3G and H). Therefore, simultaneously silencing Fas and miR-375 might be
a potent method for inhibiting islet apoptosis and enhancing islet function under
inflammatory challenging.
Previous studies showed that primary hBMSCs failed to prevent the allogenic
rejection and maintain normal blood glucose level in the acute stage.(183) To make
this situation even worse, high blood glucose from recipient is highly toxic to
transplanted islets, which severely promotes their apoptosis.(216) Thus, promoting
islet engraftment and insulin release to downregulate blood glucose are the crucial
points for the success of islet transplantation. Our results showed that pshFas-antimiR-375 transfected hBMSCs significantly suppressed islet apoptosis and improved
islet function by suppressing Fas expression and overexpressing Mtpn compared to
other groups at the acute stage of islet transplantation (Figure 4-6H and I).
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Furthermore,

co-cultured

exosomes

suppressed

immune

rejection

at

the

transplantation sites and T cell activity (Figure 4-7). Although 100% insulin
independence was obtained, this method should be interpreted with caution because
PBMCs consist of T cells, B cells, natural killer cells, and monocytes. The roles of each
cell type during the crosstalk between hBMSC and PBMC needs to be fully understood.
The only conclusion we could make in this study is that exosomes generated from
crosstalk between hBMSC and PBMC significantly suppressed immune reaction.
However, we could not fully investigate the cell source of these immunosuppressive
exosomes. Furthermore, the dose of each factors with different functions inside cocultured exosomes needs to be accurately characterized for the safety concern.
Based on our results, we hereby propose a biotherapy and self-therapy model as
the following: (i) hBMSCs and PBMCs are isolated from the patient with type 1 diabetes
(ii) transfecting hBMSCs with pshFas-anti-miR-375 in vitro (iii) the left hBMSCs are cocultured with PBMCs, followed by exosomes isolation from the co-cultured media, (iv)
patient receives donor islets co-transplanted with pshFas-anti-miR-375 transfected
hBMSCs, and (v) co-cultured exosomes are injected to suppress immune rejection. In
summary, our studies demonstrate that hBMSCs and co-cultured exosomes might be
an efficient small RNA delivery vehicle and immunosuppressive product for human
islets and become a promising strategy to improve the outcome of islet transplantation.
4.5. CONCLUSION
Co-delivery of siFas and anti-miR-375 by hBMSCs and derived exosomes

109

suppressed early apoptosis of transplanted human islets, while further immune activity
could be suppressed by intravenously injection of hBMSC and PBMC co-cultured
exosomes. This gene & cell therapy by hBMSC and derived exosomes might be a
potent method for the improvement of islet transplantation.
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS
5.1. SUMMARY
Prostate cancer is the most pervasive malignancy in man and remains the second
leading cause of cancer-related death of men in United States. Since androgen plays
important role of tumor growth at the beginning, androgen-related therapy is the first
choice for prostate cancer treatment. However, traditional antiandrogen reagent could
not inhibit mutated androgen activity. Thus, we developed bicalutamide analog
CBDIV17 for better inhibiting the proliferation of prostate cancer cells and tumor growth
in vivo. Treatment with paclitaxel as another widely used chemotherapy reagent may
also lead to chemoresistance, especially in metastatic tumor cells. We indicated that
miR-34a as a tumor suppressor miRNA is downregulated in the process of prostate
cancer. Thus, rubone as a recently screened small molecule miR-34a modulator is
used for combination therapy with paclitaxel to treat metastatic and PTX-resistant
prostate cancer. Using an orthotopic prostate cancer model, we demonstrated that
PTX and rubone combination therapy could suppress tumor growth by restoring miR34a and the downstream gene expression. Since CBDIV17, PTX, and rubone are all
highly hydrophobic drugs, we used previously synthesized PEG-PBC and PEG-PCD
to form micelles for drug delivery. To enhance the drug delivery efficacy, LHRH was
conjugated to PEG-PBC to target prostate cancer cells in vivo. Our results indicated
that our formulations could suppress tumor growth in subcutaneous model or PTXresistant tumor growth in orthotopic model, respectively.
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For the treatment of T1D, islet transplantation is still hindered by immune rejection
and PNF. To address these two problems, we co-delivered siFas and anti-miR-375 to
inhibit islet apoptosis and promote transplanted islet function. Since traditional RNA
delivery vehicles including lipid-like polymers and viral vectors have low transfection
efficacy or insertional oncogenic potential respectively, we used hBMSCs and their
exosomes as novel gene delivery platform. We first construct a plasmid encoding siFas
and anti-miR-375 for hBMSC transfection, followed by demonstrating the RNA delivery
pathway and evaluating delivery efficacy. To further suppress the post-transplantation
immune rejection, we used a humanized NSG mouse model to mimic the activity of
immune system and hBMSC & PBMC co-cultured exosomes to suppress the T cell
activity. hBMSCs could deliver RNA to human islets by direct touch and exosome,
which is demonstrated by using dye labeled siRNA or spinach aptamer linked shRNA.
Simultaneously silencing Fas and miR-375 promoted insulin release and suppressed
islet apoptosis caused by cytokine cocktail. In a humanized mouse model, pshFasanti-miR-375 transfected hBMSCs suppressed early apoptosis of transplanted islet
and intravenous injection of hBMSC & PBMC co-cultured exosome, which could better
suppress T cell activity compared to hBMSC exosomes due to high HGF and
immunosuppressive miRNA amount, suppressed immune rejection after islet
transplantation. We obtained a 100% insulin independence within 3 months of islet
transplantation and suppressed T cell infiltration of transplanted islets with improved
function and suppressed apoptosis.
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5.2. FUTURE DIRECTIONS
The findings presented in this thesis demonstrated that PEG-PBC or PEG-PCD
formed micelles could simultaneously carry hydrophobic drugs or further perform
target delivery for different stages of prostate cancer. Systemic administration of these
formulations significantly prolonged the half-life and bioavailability of the anti-cancer
drugs and more tumor accumulation. The development of analogs from current used
drugs might give us new idea for cancer therapy. Furthermore, the newly screened
rubone for HCC therapy could be a potent therapeutic agent for treating PTX-resistant
prostate cancer. However, the miR-34a regulation mechanism of rubone has not been
well studied. In the future, we will further silence Tap73 and Elk-1 to determine if the
effect of rubone can be diminished. Except for enhancing Tap73 and Elk-1 expression,
rubone might also regulate the protein-protein or protein-miR-34a interaction, including
Tap73 and MDM2, or Tap73 and miR-34a precursor. We will also determine this effect
in our future study.
In our diabetes project, we used an RNA mimic of GFP to link shRNA for tracking
the RNA generation and delivery pathways from hBMSCs to human islets. Actually,
this shFas-spinach needs to be further evaluated. For example, we need to evaluate if
the Fas silencing efficacy is affected after spinach linking. If not, this kind of spinachlinked shRNA or miRNA could be further used to develop bifunctional oligonucleotide,
which could both tracking the location and silencing genes. The only problems are the
low fluorescent signal and the compound for monitoring fluorescent is needed, not an
automatic fluorescent. On the other hand, the application of exosome for RNA delivery
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in T1D is still limited since we could not avoid the usage of hBMSC. We should further
optimize exosome isolation method to get enough amount of exosome for RNA delivery
to human islet to finally succeed in cell-free therapy.
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